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Executive Summary 
Extravehicular activity (EVA) is at the core of a manned space exploration program. Some elements of 
exploration may be safely and effectively performed by robots, but certain critical elements will require 
the trained, assertive, and reasoning mind of a human crewmember. To effectively use these skills, 
NASA needs a safe, effective, and efficient EVA component integrated into the human exploration 
program. The EVA preparation time should be minimized and the suit pressure should be low to 
accommodate EVA tasks without undue fatigue, physical discomfort, or suit-related trauma. 
Commissioned in 2005, the Exploration Atmospheres Working Group (EAWG) had the primary goal of 
recommending to NASA an internal environment that allowed efficient and repetitive EVAs for missions 
that were to be enabled by the former Constellation Program. At the conclusion of the EAWG meeting, 
the 8.0 psia and 32% oxygen (O2) environment were recommended for EVA-intensive phases of 
missions.  
As a result of selecting this internal environment, NASA gains the capability for efficient EVA with low 
risk of decompression sickness (DCS), but not without incurring additional negative stimulus of 
hypobaric hypoxia to the already physiologically challenging spaceflight environment. This paper 
provides a literature review of the human health and performance risks associated with the 8 psia / 32% 
O2 environment. Of most concern are the potential effects on the central nervous system including 
increased intracranial pressure, visual impairment, sensorimotor dysfunction, and oxidative damage. 
Other areas of focus include validation of the DCS mitigation strategy, incidence and treatment of acute 
mountain sickness (AMS), development of new exercise countermeasures protocols, effective food 
preparation at 8 psia, assurance of quality sleep, and prevention of suit-induced injury.  
As a first effort, the trade space originally considered in the EAWG was reevaluated in an effort to find 
ways to decrease the hypoxic dose by further enriching the O2% or increasing the pressure. After 
discussion with the NASA engineering and materials community, it was determined that the O2 could be 
enriched from 32% to 34% and the pressure increased from 8.0 to 8.2 psia without significant penalty. 
These two small changes increase alveolar O2 pressure by 11 mmHg, which is expected to significantly 
benefit crewmembers. The 8.2/34 environment (inspired O2 pressure = 128 mmHg) is also 
physiologically equivalent to the staged decompression atmosphere of 10.2 psia / 26.5% O2 (inspired O2 
pressure = 127 mmHg) used on 34 different shuttle missions for approximately a week each flight. Once 
decided, the proposed internal environment, if different than current experience, should be evaluated 
through appropriately simulated research studies. In many cases, the human physiologic concerns can 
be investigated effectively through integrated multi-discipline ground-based studies. Although missions 
proposing to use an 8.2/34 environment are still years away, it is recommended that these studies begin 
early enough to ensure that the correct decisions pertaining to vehicle design, mission operational 
concepts, and human health countermeasures are appropriately informed. 
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Purpose 
The purpose of this report is to evaluate the human health and performance implications associated 
with the proposed exploration environment of 8.0 psia / 32% O2 through a combination of literature 
review and analysis. 
Background 
Over the past several decades, NASA has operated spacecraft habitable elements and spacesuits at a 
variety of different atmospheres. Early missions during the Gemini and Apollo programs were short 
duration and relied on low pressure, pure O2 environments. Skylab missions were longer in duration, but 
still employed a low pressure (5 psia), high O2 (70%) environment. NASA’s more recent programs, 
including the Space Shuttle Program and International Space Station (ISS) programs have operated at an 
Earth equivalent sea level atmosphere of 14.7 psia and 21% O2. Selection of this atmosphere facilitated 
international partnerships and allowed in-flight scientific studies to have ground-based controls, with 
gravity as the primary variable of interest.  
In 2005, the EAWG was convened to formulate recommendations on the designs of habitable internal 
environments to feed requirements for the development of vehicles during the Constellation Program 
[1]. The process used to select among several candidate environments is detailed in the EAWG final 
report, which was first published as an internal NASA document [2] and then later as a NASA Technical 
Paper [1]. The primary trade space applied to the EAWG analysis for the lunar and Mars habitat and 
surface spacesuit designs were hypoxia, flammability, and DCS. 
The EAWG recommendations were as follows: 
 Launch and transport vehicle should operate within the existing ISS and shuttle standard 
environment designs of 14.7 psia / 21% O2 and 10.2 psia / 26.5% O2  
 Lunar and Mars landers should operate at both 10.2 psia / 26.5% O2 and 8.0 psia / 32% O2 
 Surface spacesuits should operate at 100% O2 and at a pressure range of 3.5 to 8.0 psia 
 Long-duration lunar and Mars habitats should operate at 8.0 psia / 32% O2 nominally with an 
option to depress further to 7.6 psia / 32% O2  
 Atmospheric recommendations assumed a control box of ± 0.2 psia total pressure and ± 2.0% O2 
concentration 
The consensuses coming out of the EAWG were the recommendations for a lower pressure surface 
habitat and a surface spacesuit with a variable operating pressure range. The 8 psia / 32% O2 
(henceforth referred to as 8/32) environment was selected because it was considered to be a mildly 
hypoxic dose with acceptable flammability risk and low O2 prebreathe overhead to maintain acceptable 
DCS risk [1]. The proposed forward work related to human physiology was almost solely related to DCS, 
with no mention of hypoxia research. 
The EAWG recommendations were developed through a multi-discipline working group and concurred 
upon by the heads of the Johnson Space Center (JSC) Engineering, Space and Life Sciences, and Flight 
Crew Operations Directorates as well as the manager of the JSC Extravehicular Activity Office. However, 
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attempts to move forward with vehicle designs based on the EAWG report were met with mixed 
approval because the recommendations were not captured anywhere outside of the Constellation 
Program documentation. Mixed approvals were the case until the recent memorandum by NASA Human 
Exploration and Operations Mission Directorate (HEOMD) Associate Administrator, which directed 
programs under HEOMD to begin the work to enable the updated Exploration Atmosphere of 8.2 psia 
and 34% O2 [3]. Although forward work will focus on the 8.2/34 environment, the purpose of this paper 
is still to document the human health and performance impacts of the 8/32 environment. 
Understanding these potential impacts led to the less-hypoxic 8.2/34 environment and highlights the 
remaining human performance concerns that still need to be addressed to enable an Exploration 
Atmosphere for long-term human habitation. 
Why and When 8/32 
Multiple reasons were proposed for the use of the 8/32 environment. A primary benefit of this 
atmosphere is a reduction in O2 prebreathe requirements for EVA. With the 8/32 option, it is expected 
that a 15-minute prebreathe may be all that is necessary to achieve acceptable risk of DCS during EVA. 
An 8 psia cabin pressure also allows operational use of a suitport, which greatly reduces the complexity 
and overhead associated with EVA suit donning. The current expectation is that an astronaut could don 
the EVA suit through a suitport and complete all necessary checkout procedures and EVA prep during 
this 15-minute prebreathe window. Also, suitport-compatible suits are proposed to be variable-pressure 
suits capable of operating from the 8 psia cabin pressure down to the expected EVA-operating suit 
pressure of 4.3 psia. A variable-pressure suit also provides immediate treatment capability for DCS, 
because the suit could be repressurized to 8 psia in the field without requiring reentry into the cabin. 
Furthermore, the short transition times between suit and cabin allow for intermittent recompressions, 
further reducing the risk of DCS. 
Beyond control of DCS to acceptable risk levels, the 8/32 environment coupled with suitport operations 
is a paradigm shift from NASA’s ISS and shuttle EVA protocols. Unlike the ISS construction and 
maintenance EVAs, which were well understood and very specific, exploration EVAs will be driven by 
choices made at the destination. Exploration crews need a robust and flexible EVA capability, which is 
provided by coupling the 8/32 environment with suitport operations. This combination provides an on-
demand EVA capability including short-duration EVA, multiple EVAs per day, and single-person EVA. 
Application of the 8/32 environment is only needed during high EVA-frequency phases of a mission. The 
8/32 environment is not needed for launch or transit to the destination, although the capability should 
be considered for all habitable elements to ensure transitions between different elements can be 
accomplished during contingency situations. Currently, any element expected to operate at the 8/32 
environment (other than the EVA suit) will also be capable of repressurizing and operating at 14.7 psia 
and 21% O2.  
Important Changes since the 2006 EAWG Final Report 
Much has changed at NASA since the 2006 EAWG recommendations, including cancellation of the 
Constellation Program, development of the Multi Mission Space Exploration Vehicle (MMSEV) concept, 
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movement toward a Capability-Driven Framework for space exploration, advances in our understanding of 
human adaptation to the spaceflight environment, and the identification of new human risks and hazards.  
Constellation Program Cancellation 
One of the largest changes since the EAWSG was the cancellation of the Constellation Program. This 
program featured a clear target at the moon with rapidly evolving operational concept development. 
The requirement for an Exploration Atmosphere of 8/32 was kept in the Constellation Architecture 
Requirements Document. It is difficult to quantify how much this affected implementation of the EAWG 
recommendations for vehicle requirements, research, and development. It could be that discontinuity 
with personnel in the intervening years coupled with a change from a well-defined lunar target to a 
Capability-Driven Framework contributed to some of the concerns about using the EAWG report as an 
approved baseline.  
MMSEV and Suitport Development 
Over this same time period, new space exploration vehicles and spacesuits were designed and 
developed in accordance with the recommendations from the EAWG. One of these vehicles is the 
MMSEV, which initially started out as a small pressurized rover for the lunar environment. It has since 
developed additional capability beyond lunar and Mars surface operations to now include variants with 
operating capacity in the microgravity environment as well, either as a way-station habitat or as a near-
Earth asteroid (NEA) exploration vehicle. The MMSEV assumed the 8/32 environment as the NASA 
baseline and has developed both the suitport and a variable pressure rear-entry suitport compatible 
EVA suit. Use of a variable pressure EVA suit with suitport enabled by the 8/32 internal environment 
yields several benefits. From an operational standpoint, NASA gains the capability for single-person EVA, 
short EVA, multiple EVAs in a single day, enhanced waste removal using a suitport transfer module, 
reduced consumables, and high work efficiency index. In terms of safety, there is reduced overhead for 
meeting acceptable DCS risk, multiple vehicle reentry points, and immediate capability for DCS 
treatment through repressurization of the EVA suit.  
Corrected EAWG Equivalent Air Altitudes 
One reason for the general agreement in the 2005 to 2006 timeframe was that the 8/32 environment 
represented a mild hypoxic exposure because the assigned equivalent air altitude (EAA) was thought to 
be 1,524 m (5,000 ft) [1] [2]. However, the EAA was based on ambient dry-gas partial pressure of O2 
(ppO2) instead of inspired O2 partial pressure (PIO2) under conditions where the fraction of inspired O2 
(FIO2) was ≠ 0.209. In other words, the breathing gas was not air but enriched O2 at low ambient 
pressure (PB). Simply referencing an air altitude table with the correct hypoxic ppO2 [4] did not 
completely account for the contribution of water vapor partial pressure (PH2O) found to reduce ppO2 at 
higher altitude. The error was recently discovered, long after completing the in-house and external 
reviews of recommendations from the EAWG. 
The EAA for the 8/32 environment is actually slightly more than 1,830 m (6,000 ft), which properly 
accounts for a water vapor pressure (PH2O) of 47 mmHg at 37°C (98.6°F) to reduce ppO2 at 8.0 psia 
while breathing 32% O2. The computed PIO2 for this condition is 117 mmHg through the equation: PIO2 = 
(PB – 47) * FIO2, where PB is ambient pressure of 414 mmHg (8.0 psia), 47 mmHg is PH20, and FIO2 is 0.32, 
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the dry-gas fraction of inspired O2. A PIO2 of 117 mmHg is equivalent to breathing air at an altitude of 
1,880 m (6,170 ft), as indicated in the air altitude table (Figure 1) [5]. Most experts would still consider 
this exposure mild hypoxia.  
 
Figure 1. Equivalent Air Altitude Table. 
In the EAWG report (NASA TP-2010-216134) [1], there are several instances (page 1, page 16 Table 10, 
page 116) and various places in JSC-63309 [2]), where the assigned EAA was based on ambient dry-gas 
ppO2 instead of PIO2 under conditions where FIO2 was ≠ 0.209. Table 1 lists the atmospheres in Table 10 
from NASA-TP-2010-216134 and shows the incorrect EAA based on ppO2; Table 2 shows the correct EAA 
based on PIO2. The correct values for EAA should be substituted for the incorrect values when one reads 
References 1 or 2. Both of these tables use the equations where ppO2 = PB * FIO2 and PIO2 = (PB - 47) * 
FIO2. 
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Physiologists talk about O2 partial pressure in terms of “wet” inspired O2 partial pressure, designated as 
PIO2, or even alveolar O2 partial pressure (PAO2). As evidence, PIO2 is how the risk of AMS is discussed in 
the Conkin and Wessel critique of the equivalent air altitude model [6]. Engineers talk about O2 partial 
pressure in terms of dry-gas ambient O2 partial pressure, designated as ppO2. Engineers prefer ppO2 
because this is what Environmental Control and Life Support Systems (ECLSS) O2 sensors provide. This 
results in potential confusion when interpreting hypoxic ppO2, especially when an FIO2 ≠ 0.209 is 
combined at higher altitude while the contribution of saturated tracheal water vapor pressure at 
reducing PIO2 becomes increasingly more significant at lower PB. 
For example, the current NASA STD 3001 Vol. 2 (V2 6003, below) requires a sustained ppO2 of 155 
mmHg (3.0 psia) or higher. At 8.0 psia, an ECLSS sensor would read 155 mmHg and meet this standard, 
but the PIO2 would be slightly hypoxic at 137 mmHg (normoxic PIO2 = 149 mmHg). Modification of this 
NASA standard is required in two ways. First, if the overall goal is to maintain physiologic normoxia, then 
the standard should be updated into a table that accounts for differences in ppO2 and PIO2 as a function 
of PB and the lung PH20 of 47 mmHg should be included. Second, the use of an alternative exploration 
environment, such as 8/32, is currently precluded by this standard. Thus, the standard needs to be 
updated to reflect that for certain high EVA content phases of a mission, a mildly hypoxic environment 
can be used for a given period of time. Research will be needed to determine the acceptable duration 
for an alternative exploration environment.  
“6.2.1.2 O2 Partial Pressure Range for Crew Exposure [V2 6003] 
The system shall maintain ppO2 to within the physiologic range of 20.7 kPa < ppO2 ≤ 50.6 kPa (155 
mmHg < ppO2 ≤ 380 mmHg, 3.0 psia < ppO2 ≤ 7.35 psia). Rationale: The system needs to maintain 
ppO2 to the specified range throughout all non-joint operations, docked operations, and EVA. The 
range provided is the physiological values for indefinite human exposure without measurable 
impairments to health or performance.” 
Table 1. Incorrect EAA Based on ppO2 
PB psia (mmHg) FIO2 ppO2 psia (mmHg) Incorrect EAA (m) Incorrect EAA (ft) 
10.2 (527) 0.265 2.70 (140) 1067 3,500 
8.0 (414) 0.32 2.56 (132) 1524 5,000 
7.6 (393) 0.32 2.43 (126) 1981 6,500 
 
Table 2. Corrected EAA Based on PIO2 
PB psia (mmHg) FIO2 PIO2 psia (mmHg) Incorrect EAA (m) Correct EAA (ft) 
10.2 (527) 0.265 2.46 (127) 1268 4,160 
8.0 (414) 0.32 2.27 (117) 1880 6,170 
7.6 (393) 0.32 2.14 (111) 2286 7,500 
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Independent Pressure Effect on Hypoxic Dose 
Although not a new debate, recently there has been considerable discussion on whether normobaric 
hypoxia (NH) elicits the same hypoxic symptoms as hypobaric hypoxia (HH) [7] [8] [9]. In many cases, the 
differences may not reach statistical or clinical significance, but the general trend is one that seems to 
indicate that almost all measurable changes associated with hypoxic exposures trend worse in the case 
of HH as compared to NH. Given that the 8/32 environment is an engineered environment and does not 
exist in nature; a standard EAA may not be fully representative of the hypoxic stress. An 8 psia PB is 
associated with an actual altitude of 4,877 m (16,000 ft). It is the enrichment of O2 from 21% to 32% that 
reduces the hypoxic stress to an EAA of approximately 1,830 m (6,000 ft). It is unknown whether the 
increased hypobaric exposure will increase the hypoxic dose, but at least one literature review 
suggested that the 8/32 environment increased the risk of one known hypoxic symptom, AMS, from the 
proposed EAA of about 1,830 m (6,000 ft) to 2896 m (9,500 ft) [10]. This hypothesis is based on 
literature review and a proposed model and has not been validated, but it does point to the need for 
human exposure research in the 8/32 environment. A more recent review lends further support that NH 
and HH are not equivalent for acute and subacute exposures and suggests that using NH as a surrogate 
for HH during chronic exposures is inappropriate [11]. 
Research is warranted to evaluate a possible PB effect on hypoxic adaptations. Results from these 
studies will aid in the understanding of human physiology in the 8/32 environment as well as inform the 
scientific community on how best to proceed with hypoxia research. In research settings, it is easier to 
design and operate systems that manipulate PIO2 by FIO2 rather than PB. However, in situations where 
the PB effect is significant, then human or animal research will require true ascent-to-altitude or 
hypobaric chamber studies. 
Visual Impairment / Intracranial Pressure Syndrome 
Because of its prevalence and potential mission impact, visual impairment / intracranial pressure (VIIP) 
is considered the top human system risk in the ISS Program. Currently, VIIP is a poorly understood 
syndrome with potential for permanent damage to the ocular and central nervous systems. The changes 
that have been observed to date are developing in microgravity without additional exposure to HH. 
While the pathophysiology of VIIP is under active investigation, the addition of HH to the spaceflight 
environment may exacerbate the problem.  
Elevated Carbon Dioxide on ISS 
Elevated carbon dioxide (CO2) is a known problem in a closed system with humans in the loop. On Earth, 
the ambient CO2 concentration is about 0.23 mmHg (0.03%). In spacecraft, it is not practical to control 
CO2 to such low levels because of power and consumable constraints, and CO2 levels on the ISS have 
typically been 2.3 to 5.3 mmHg (0.5 ± 0.2%), a ten-fold increase compared to terrestrial levels [12]. Over 
the years, ISS crewmembers have been found to develop CO2-related symptoms such as headache and 
lethargy at lower-than-expected CO2 levels, and symptoms tend to resolve when ambient CO2 is 
decreased [13]. While work to quantify this association is ongoing, chronic CO2 exposure appears to be a 
contributing factor to several in-flight medical issues, including VIIP [13] [14]. The CO2 elevation will 
likely complicate the adaptation to a mildly hypoxic environment, potentially making physiologic 
symptoms worse. 
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Literature Review and Design Reference Mission Considerations 
Representatives from NASA’s Human Research Program (HRP), EVA Physiology Laboratory, and Space 
Medicine Group contributed different points of view and areas of expertise to this report. The focus was 
to evaluate the expected and possible human impacts related to living in space at the proposed 8/32 
environment. To evaluate potential risk, the team reviewed literature from their respective disciplines 
on the effects of mild hypoxia, primarily from research done at altitudes of 1,830 to 3050 m (6,000 to 
10,000 ft). The 8/32 environment does not exist in nature, but approximates to an EAA of about 1,880 m 
(6,000 ft). Control box (32 ± 2%) uncertainty stretches the possible EAA to 2,438 m (8,000 ft). Finally, the 
possibility of an independent pressure effect on hypoxia has been proposed, with one model proposed 
in a review suggesting that the 8/32 environment would present an AMS risk of 2,896 m (9,500 ft) [10]. 
In some cases, literature from higher altitudes was reviewed if no literature was available at the lower 
altitude range.  
Design Reference Missions 
Nine representative design reference missions (DRMs) have been proposed by the Human Spaceflight 
Architecture Team as a notional program to extend human presence beyond low-Earth orbit (LEO), to 
the Cis-Lunar space, near-Earth asteroids (NEAs), the Martian moons, and Mars. As Table 3 shows, these 
exploration missions will have four to six crewmembers, last up to 1,200 days, and baseline many EVAs 
for surface missions.  
 
The principal goal is to maintain the crewmembers’ health so they can accomplish their mission 
objectives. This means a robust health maintenance program that provides countermeasures against the 
known physiologic changes to both the space environment (hypogravity and hypercapnia) and the 
proposed spacecraft environment (HH), and medical care capability that is commensurate with the 
duration of the mission, communication delays, and distance from definitive medical care facilities. 
Thus, those missions beyond LEO that will last more than 1 to 2 weeks (DRM 5-9) will require 
increasingly autonomous medical capability with increasing distance from Earth. At the same time, we 
recognize that some physiologic questions cannot be answered until crews start flying these missions, or 
Table 3. Representative Design Reference Missions (modified from: “Focused Human Exploration Design 
Reference Missions,” M. Rucker and L. Toups, 3 May 2012) 
DRM Destination Duration Crew EVA? Year 
1  Lunar Orbit  7 to 10 days  0  None  2017  
2  Lunar Orbit  10 to 14 days  4  None planned  2021  
3  Cis-Lunar  TBD  0  None  <2027  
4  LEO  <21 days  4  TBD <2027  
5  Cis-Lunar  30 to 180 day  4  Contingency  <2027  
6  Asteroid  <365 days  4  Few  >2025  
7  Lunar Surface  <33 days  4  Many  >2025  
8  Mars Moon  600 to 1200 days  4-6  TBD >2035  
9  Mars Surface  Up to 1,140 days  4-6  Many  >2035  
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until simulations of certain mission factors are performed on the ISS; therefore, engineering and 
operational controls should be in place to prevent such known issues as rapid transitions between 
atmospheres and chronically elevated CO2 levels. 
EVA Frequency and Spaceflight Considerations 
The planned scenarios currently being considered for future missions using the 8/32 environment 
involve a high number of EVAs. Although all of these scenarios will have a heavy EVA phases, this phase 
may take place at very different points in a mission. Crewmembers can reach the lunar surface or a Cis-
Lunar location within a few days. On the other hand, it will take several months to reach a NEA or Mars. 
Therefore, we have to consider the operational tempo and known physiologic changes as we look to 
potential impacts of the inclusion of the 8/32 environment.  
In the lunar and Cis-Lunar cases, spaceflight data from shuttle missions should be leveraged. In these 
cases, the transition to the 8/32 environment would superimpose adjustments to the hypobaric hypoxic 
environment with adjustments associated with adaptation to microgravity. The concern is that the 
combination of these adjustments in addition to a heavy-EVA mission profile may degrade the health 
and performance of astronauts who must maintain a high level of proficiency to accomplish mission 
goals [15]. The first 2 weeks of a spaceflight is a period of dynamic physiologic change in the 
crewmember. Primarily, physiologic adaptation to the new spaceflight environment includes: cephalad 
fluid shift, neurovestibular adaptation, susceptibility to space motion sickness, and changes in spatial 
orientation. These changes result in physical symptoms such as increased fatigue, headaches, reduced 
sleep, lack of appetite, back pain, etc., all of which can negatively impact mood and behavior. Cognitive 
processes such as focus and attention, memory recall, problem solving, and executive function may 
affect mission operations, which include highly technical and complex procedures [16].  
Space Shuttle missions, which typically lasted about 2 weeks, were regarded as high workload and fast-
paced, with little to no time available for “winding down” [17]. Crewmembers reported forgoing eating 
and sleeping to complete timeline objectives [18] [17]. Accordingly, objective data from spaceflight 
indicate that shuttle astronauts slept an average nightly duration of approximately 6 hours [19]. The 
increase in stress response and sleep deprivation increases the likelihood of errors. Therefore, effects of 
the slightly hypoxic environment must be considered with these operational data in mind. It could be 
expected that more severe detriments would result from the inclusion of a hypoxic environment. 
In the NEA and Mars cases, spaceflight data from ISS missions will be more appropriate for analysis. It 
will take up to 6 months to reach these locations, which nicely parallels the current length of an ISS 
mission. At the end of a 6-month ISS rotation, the crewmembers are going to be acclimatized the 
spaceflight microgravity environment; therefore, the problem of complicating the adaptation to 
spaceflight with the 8/32 environment is avoided. But the long-term issues associated with spaceflight 
will pose different challenges. Crewmembers may have signs or symptoms of the VIIP syndrome. They 
may have decrements in cardiovascular, muscular, and aerobic capacity if the current ISS 
countermeasures effectiveness cannot be maintained during transit. Transitioning to the 8/32 
environment in the midst of returning to a gravity environment (3/8-g on Mars) and adding a heavy EVA 
phase to the mission after months in space is a scenario where we have no operational experience. 
10 
 
Expected problems are less likely going to stem from acute overload, but rather the combination of 
negative chronic spaceflight adaptation that may worsen with exposure to a mildly hypoxic environment 
coupled with an increased EVA frequency. 
Hypoxia-Mediated Physiologic Concerns 
This section will discuss the physiologic concerns and impacts related to the expected hypoxic dose of the 
8/32 environment. Decreasing the O2 delivery to all the bodily organs and systems has an impact on all 
physiologic functions. However, the 8/32 environment only induces a mild hypoxic stimulus, which we 
would not be concerned about in itself on the surface of the Earth. We know that humans adapt well to 
altitude with a similar ambient O2 partial pressure as the 8/32 environment. Such an environment in 
combination with other spaceflight factors such as microgravity and space radiation is; however, of 
concern, because the additive and/or synergistic effects might impair human health and performance to 
an unacceptable risk level. In particular, the effects on brain and ocular physiology are of concern, because 
we lack knowledge as to how a decrease in ambient O2 partial pressure – however mildly – in space might 
affect the pressure in the brain and eyes and thus human performance. In addition, we do not know how 
the combinatorial effects of a mildly hypoxic atmosphere and mildly hyperoxic EVA suit atmosphere affects 
cellular pathways, and whether it induces oxidative stress and damage threatening human health to an 
unacceptable level. Consequently, the addition of mild hypoxia and its effect on the human system will be 
needed to augment existing NASA human research. Particular emphasis should be placed on brain and 
ocular function, sensorimotor performance, and cellular oxidative stress and damage. 
Vision Impairment / Intracranial Pressure Syndrome 
The VIIP syndrome was first described in 2006 with the observation of papilledema, vision changes, and 
increased intracranial pressure in long-duration astronauts returning from the ISS. However, postflight 
questionnaires obtained between 1989 and 2011 revealed that 23% of shuttle and 48% ISS long-
duration mission astronauts reported a subjective degradation in vision [20], suggesting that spaceflight-
induced visual impairment and intracranial hypertension may have been occurring in astronauts 
although the syndrome was not recognized until the technology advanced sufficiently to evaluate and 
look for it [21]. Based on a case definition developed by expert consensus, 15 cases have been identified 
out of 36 long-duration astronauts to date, although not all of these 36 astronauts have been fully 
evaluated. Although direct in-flight measurements have not been made, in-flight signs of papilledema, 
and postflight changes in brain imaging have documented evidence of elevated intracranial pressure 
(ICP). In addition, postflight lumbar puncture in four ISS crewmembers has indicated elevated ICP 
ranging from 21.0 to 28.5 cmH2O (normal range: 5 to 15 cmH2O). Of note, ICP may remain elevated long 
after flight in some of the returning symptomatic astronauts, over 18 months in one case [20]. 
Microgravity exposure induces a cephalad fluid shift likely resulting in elevated ICP. It is possible that the 
cephalad fluid shift accounts for a 50% increase in ICP in the microgravity environment compared to 1-g 
[22]. In addition, it is known that the average CO2 level is elevated on the ISS, which may further 
increase ICP due to its potent vasodilator effects. Up to an additional 12% increase in ICP may be 
attributed to current CO2 levels on ISS [23]. Thus, a combination of the microgravity-induced cephalad 
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fluid shift and high ambient CO2 levels very likely increases ICP in astronauts leading to known visual 
acuity problems and possible impact on cognitive brain function.  
One concern of HH alone is AMS (to be discussed further), which lies within the spectrum of high-
altitude headache to high-altitude cerebral edema. High-altitude cerebral edema is associated with 
increased ICP [24] [25] [26]. AMS itself appears to be strongly associated with increased optic nerve 
sheath diameter reflecting increased ICP [27]. Sutherland, et al. found that the optic nerve sheath 
diameter increased in 13 mountaineers from sea level to exposures at 2000, 3700, 5200, and 6400 m 
(6562, 12139, 17060, and 20997 ft) [28]. Increasing optic nerve sheath diameter has been found to 
correlate positively with ICP and is based on the fact that the subarachnoid cerebrospinal fluid (CSF) 
compartment communicates with the perioptic CSF space. Therefore, increases in intracranial CSF 
pressure are transmitted to the perioptic CSF space and may be measured as changes in the optic nerve 
sheath diameter. More directly, Yang, et al. found that upon exposure to an altitude of 4,000 m (13,123 
ft) for 2 hours, ICP measured by intraventricular catheter increased by 78% from 15.4 to 27.4 cmH2O in 
hypoxic goats compared to nonhypoxic goats [29]. Physiologically, any fall in O2 delivery results in 
vasodilation of cerebral vessels to increase brain blood flow and elevate ICP. With the addition of 
microgravity-induced intracranial hypertension, it is likely that astronauts would develop greater 
increases in ICP in an 8/32 environment than in 14.7/21. Even limited exposures to 8/32 may exacerbate 
VIIP in an additive or synergistic manner. 
At present, 42% of ISS crewmembers are affected by the VIIP syndrome and 15% of those severely in a 
normobaric, normoxic (14.7 psi/20.9% O2) environment. Because of its prevalence and potential mission 
impact due to visual and central nervous system (CNS) impairment, VIIP is considered the top human 
system risk in the ISS Program. It should be noted that the changes that have been observed to date are 
developing in microgravity without additional exposure to HH. The combinatorial effects of the 
spaceflight environmental factors such as microgravity and high ambient CO2 levels with an 8/32 
environment are unknown and could potentially negatively impact brain blood flow and cognitive 
abilities based on current knowledge of the VIIP syndrome.  
Moreover, in the setting of papilledema, hypoxia is expected to worsen optic nerve ischemia. Hypoxia at 
altitude is associated with optic disc swelling, hypothesized to be due to a hypoxia-induced increase in 
cerebral blood flow that disrupts the blood-brain barrier and results in cerebral edema [30] [31]. 
Altitude-associated optic disc swelling has been described since 1969 [26]; a recent study of 27 high-
altitude mountaineers by Bosch, et al. [30] found optic disc swelling in 59% of the climbers. 
Furthermore, high-altitude retinopathy, typically described as retinal vascular engorgement and 
tortuosity, can be associated with decreased visual acuity and cotton wool spots [32], two of the 
diagnostic hallmarks of VIIP [21]. There is enough overlap between spaceflight-induced VIIP and altitude 
illnesses to warrant precaution about intentionally adding HH to spaceflight. The concern is that an 8/32 
environment would worsen visual changes, potentially leading to decreased ability to perform tasks and 
possible permanent damage. 
As a result, we are concerned about an 8/32 environment for durations longer than a week, before we 
know more about the mechanisms of the VIIP syndrome and how to mitigate this risk. As forward work 
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relating to the 8/32 environment, we suggest adding an experimental arm to the current VIIP research 
plan, both regarding animal and human studies, to understand the additive or synergistic effects of the 
8/32 environment with known spaceflight factors to the VIIP syndrome. 
Sensorimotor Performance 
Sensorimotor Performance during Spaceflight 
Astronauts experience disturbances in sensorimotor function during periods of adaptive change on 
initial exposure to microgravity and on return to a gravity environment. These disturbances include 
spatial disorientation, space motion sickness, alterations in gaze control, and postflight postural 
instability, and gait ataxia [33] [34] [35] [36] [37] [38]. Importantly, sensorimotor disturbances are more 
profound as duration of exposure to microgravity increases. These changes can impact in-flight 
operational activities including spacecraft landing, docking, remote manipulation, and EVA performance. 
In addition, postflight postural and gait instabilities could prevent or extend the time required to make a 
nominal or an emergency egress from a spacecraft. 
Sensorimotor Performance and Hypoxia 
The retina is extremely sensitive to changes in O2; therefore, acute hypoxia can lead to decrement in 
visual function. These changes are less profound in the mild hypoxic range; however, performance 
decrements have been observed [39]. In one study that focused on visual performance specifically in the 
hypoxic range of 1,830 to 2,438 m (6,000 to 8,000 ft), mesopic vision was impaired [40]. Mesopic vision 
is visual performance in low-light levels but not quite dark conditions, equivalent to that experienced 
during twilight. Given potential low-light conditions during planetary operations, this decrease in visual 
performance may have operational implications.  
Mild hypoxia has also shown to have an effect on the postural control system [41] [42] [43]. Postural 
sway measured on subjects standing on a force plate was shown to increase compared to ground-level 
controls at simulated altitudes of 1,524, 2,438, and 3,048 m (5,000, 8,000, and 10,000 ft) [41]. The 
postural control system receives input from several sensory modalities including information from 
vision, the vestibular system, proprioception from joints, tendons, and muscles, and tactile information. 
These multiple sensory informational sources are integrated in the central nervous system to aid in the 
control of postural equilibrium. Therefore, a change in postural equilibrium control can serve as a 
sensitive indicator of mild hypoxic effects on multiple sensory systems along with the efficacy of their 
central integration. 
In terms of pilot flight control performance, exposure to mild hypoxia does not have a significant impact 
on manual control ability for tasks such as maintaining assigned altitudes and navigation; however, 
procedural errors appear to increase at the 3,048-m (10,000-ft) level [44]. These events include 
misdialing frequency codes and failure to follow air traffic control instructions. In a study using self-
report questionnaires to assess hypoxic symptoms of helicopter aircrew operating at altitudes below 
3,048 m (10,000 ft), aircrew reported potentially operationally significant symptoms of hypoxia at a 
mean altitude of 2,590 m (8,497 ft) [45]. 
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During gravitational transitions, sensorimotor systems undergo adaptive changes to match motor 
output to the prevailing environment. It is currently unknown what the impact of hypoxia is on this 
essential process of sensorimotor adaptive change. Does hypoxia hinder the adaptive response 
prolonging the period of sensorimotor disturbance experienced during gravitational transitions? If 
hypoxia interacts negatively with the nominal sensorimotor adaptive process, performance decrements 
including changes in dynamic visual acuity, postural and gait instability, and spatial disorientation may 
be exacerbated, impacting performance and mission success. In addition, there are well known 
vestibular-evoked responses recorded from respiratory muscle nerves that serve to provide adjustments 
in breathing and airway patency during movements and changes in posture [46]. It is possible that 
vestibular adaptation shortly following G-transitions may negatively impact the respiratory 
compensation to the 8/32 environment. Singh, et al. [47] observed that altered vestibular function such 
as increased sway at high altitudes may reverse with acclimatization. Therefore, sensorimotor 
interactions with the 8/32 environment are likely to be more important within the first few days 
following the transitions between G states. 
Sensorimotor Performance Conclusion 
From a sensorimotor perspective, mild hypoxia can induce alterations in performance including visual 
and postural stability decrements and some alterations in piloting ability. These effects are not profound 
in terms of overall impact on performance; however, in combination with other factors unique to 
spaceflight, these performance decrements may reach threshold to impact mission capability. 
To determine whether sensorimotor adaptive mechanisms are negatively affected by the 8/32 
environment, the following studies could be done comparing the normoxic adaptive response with the 
8/32 hypoxic environment: 
 Gaze control and dynamic visual acuity adaptive responses to vision-distorting lenses 
(magnifying, minifying, etc.) 
 Manual control adaptive responses to modified joystick input 
 Gait adaptation to an unstable walking support surface 
 Combined effects of multitasking and increased G (entry profile) on adaptive responses 
If performance decrements are observed that are related to hypoxic derived reductions in ability to 
adapt sensorimotor systems, then countermeasures could be developed to mitigate these changes. One 
potential countermeasure entails hypoxic preconditioning training [48] [49] [50]. This training paradigm 
engages the endogenous mechanisms by which the brain protects itself against cerebral ischemia by 
exposing the subject to a noxious stimulus near to but below the threshold for damage. Following the 
preconditioning training, a tolerance is developed to the same or even different noxious stimulus 
beyond the usual threshold for effect. This type of training has been used successfully to develop an 
increased tolerance for ischemic stress. In this context, preconditioning to mild hypoxia could be used as 
a training countermeasure to reduce the hypoxic performance decrements associated with exposure to 
mild hypoxia and adaptive sensorimotor responses. 
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Acute Mountain Sickness  
Description  
AMS affects individuals that ascend rapidly to altitude, with symptoms such as headache, nausea, 
vomiting, disturbed sleep, and poor physical performance [15]. The acute change in ppO2 from normoxic 
(~160 mmHg) to the ppO2 of 132 mmHg associated with the 8/32 environment can result in the possibility 
that some crewmembers may develop symptoms of AMS. Between 7% and 25% of adults may experience 
mild AMS near 2,000 m (6,562 ft) [15] [51]. The risk of AMS is modified by several factors including the 
ascent rate to altitude, activity level at altitude, and individual susceptibility [52]. HH appears to induce 
AMS to a greater extent than does either normobaric hypoxia or normoxic hypobaria [53].  
AMS symptoms have been recorded using the Lake Louise symptom questionnaire (LLSQ) and include 
headache plus nausea, dizziness, fatigue, or sleeplessness that develops over a period of 6 to 24 hours. 
While expected to be mild and transient, these symptoms could potentially impact crew health and 
performance on critical mission tasks during lunar surface missions. AMS headaches are reported to be 
throbbing, bi-temporal or occipital, typically worse during the night and on awakening. This has 
implications for sleep quality. When combined with nausea, it can be likened to the flu or a hangover. 
Clinical findings confirm a change in mental status, ataxia, peripheral edema, or changes in performance 
(reduction in normal activities) [15]. 
 
 
 
 
Figure 2. Percentage participants that reached their maximum LLSQ symptoms score 
during the first 7 days at South Pole Station (2,835 m [9,300 ft]) [54]. 
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One of the largest studies on AMS was conducted by Anderson, et al. [54] during rapid ascent to 
Amundsen-Scott South Pole Station (2,835 m [9,300 ft]) in Antarctica. Of 246 subjects, 52% developed 
LLSQ defined AMS (Figure 2). Anderson et al. are currently working on some follow-up manuscripts that 
will describe the known physiological differences between the subjects who reported AMS and the 
subjects who had no AMS symptoms. The most common symptoms were shortness of breath with 
activity (87%), sleeping difficulty (74%), headache (66%), fatigue (65%), and dizziness/lightheadedness 
(46%) (Figure 3). Symptom reports at the South Pole were mild to moderate in severity with symptom 
prevalence peaking on the day after arrival at altitude (day 2, approximately 12 to 18 hours after 
arrival); yet in greater than 20%, shortness of breath with activity, fatigue and sleep problems persisted 
through day 7. This reflected conventional knowledge that symptoms appear between 6 to 48 hours 
after arrival and resolve within the first 3 days [54].  
Located on the high-plateau of Antarctica at an elevation of 2,835 m (9,300 ft), the environment of 
South Pole Station closely reflects the 8/32 environment as well as the operational profile of NASA 
mission scenarios. Most jobs at South Pole Station require physical activity, with a significant portion of 
personnel working outdoors. Activities include construction, heavy equipment operation, transport of 
supplies, science support, research, and fuel delivery [54]. This environment could serve as a high-
fidelity, ground-based analog to research hypoxic effects within a true mission-like environment. 
 
Figure 3. Severity of most commonly reported symptoms over the first week of exposure in 
personnel rapidly transported to the South Pole (2,835 m [9,300 ft]) [54]. 
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AMS Risk Specific to 8/32 Condition 
It appears through an extensive literature search [6] and statistical analysis of available data [10] that 
the 1,830-m (6,000-ft) EAA computed for the proposed 8/32 environment may have more risk of AMS 
than one would expect at this altitude. This independent pressure effect on true hypoxic dose appears 
real, and has been suspected since 1946. Ever since the derivation of the alveolar gas equation was 
published [55] there has been a physiologic foundation to expect different outcomes under normobaric 
and hypobaric hypoxia given the same hypoxic PIO2, termed the nitrogen dilution or the respiratory 
exchange ratio effect [5]. In the current context, there are two cases: the first is the equivalent air 
altitude case with assumed exposure to 1,830-m (6,000-ft) breathing air (21% O2) and the second is the 
exploration atmosphere case with exposure to 4,877 m (16,000 ft) on 32% O2. The difference between 
these two exposures is 3,048 m (10,000 ft) but the PIO2 is identical at 117 mmHg, and it appears that the 
risk of AMS is greater in the exploration atmosphere case due to the lower total pressure [10]. Without 
considering acclimatization to mild hypoxia from one vehicle to the next, there is about a 25% chance of 
AMS per crewmember for the proposed 8/32 environment [10]; this also assumes no further negative 
interactions due to adaptation to microgravity. 
Research is justified to measure the acute mild hypoxic response to the 8/32 environment. It seems that 
the magnitude of the pressure effect on true hypoxic dose is a function of the hypoxic PIO2. The pressure 
difference between 11.8 and 8.0 psia may or may not be sufficient to measure a pressure effect on the 
onset, intensity, and incidence of AMS,  given a reasonable sample of human subjects. If time and 
money resources are not available, then staged decompression and pharmacologic mitigation strategies 
should be developed to reduce and manage the predicted risk of AMS.  
Mitigations 
The most effective mitigation against AMS is prevention by slow ascent to altitude. For exploration 
missions, transitions between atmospheric pressures should be gradual to allow for acclimatization. 
However, there is no clear guidance for a transition rate at the lower equivalent altitudes associated 
with an 8/32 environment. Guidance on conservative ascent rates is usually provided for travel to high 
altitude after reaching an initial elevation of 2,438 to 3,048 m (8,000 to 10,000 ft). Beyond AMS, there 
are also DCS mitigation considerations that may have greater influence on the transition rate from 14.7 
to 8 psia. Finally, if rapid ascent cannot be avoided, pharmacologic prophylaxis may be considered 
although all medications are associated with adverse effects and contraindications.  
Acetazolamide is considered the first-line medication to prevent AMS on the ground, but it cannot be 
taken by individuals with a sulfa allergy and commonly causes paresthesias, urinary frequency [56], and 
decreased intraocular pressure, which may worsen ocular hypotony, a possible etiology of VIIP [20]. 
Dexamethasone is also recommend by the Wilderness Medical Society for AMS prophylaxis, but its use 
beyond 10 days is associated with glucocorticoid toxicity (for example, hyperglycemia and delirium) and 
adrenal suppression [57] [58], and, according to one case report, can lead to altered mental status, 
gastrointestinal bleeding, skin rash, and avascular necrosis [59]. Given these potential serious adverse 
effects, dexamethasone is generally considered second line for AMS prophylaxis and reserved for 
treatment [60]. Ibuprofen is being investigated as a prophylactic agent, but it may increase the risk of 
gastrointestinal bleeding or renal insufficiency [58]. Regardless of the agent, the potential benefits must 
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be weighed against the clinical and operational risks. Similarly, treatment options – typically descent to a 
lower equivalent altitude, O2, acetazolamide, anti-inflammatories, and steroids – will have to be 
evaluated in an 8/32 environment. 
Decompression Sickness 
DCS occurs when nitrogen (N2) (or an inert gas) comes out of solution when ambient pressure is reduced 
according to Henry’s law and bubbles cause local pressure or ischemia. Type I DCS is milder, generally 
characterized by joint pain, but can progress to the more serious type II DCS, which involve the 
cardiopulmonary and/or central nervous system. The treatment of DCS is repressurization to cabin 
pressure and supplemental O2 for mild cases and hyperbaric O2 for more serious cases. The risk of DCS is 
lowered by effective prebreathe to purge the body of N2 before EVA. New prebreathe protocols and 
treatment algorithms will need to be developed and validated for an 8/32 environment.  
DCS was a primary trade consideration during the EAWG effort [1]. We expect that the 8/32 
environment alone puts the EVA crewmember in a position where DCS risk is mitigated to acceptable 
levels with even a small amount of O2 prebreathe. This may even be the case when EVA suits are 
operated at less than 100% O2. In one analysis, the NASA Tissue Bubble Dynamics Model (TBDM) [61] 
was used to calculate the prebreathe duration required from a 10.2 psia / 26.5% O2 cabin to maintain 
the current acceptable DCS risk of 15% assuming a 4.3 psia / 95% O2 EVA suit. From the 10.2/26.5 cabin, 
a 130 minute prebreathe was required to achieve acceptable risk. In comparison, the expected 15-
minute operational prebreathe protocol from the 8/32 cabin assuming a 4.3 psia / 80% O2 EVA suit, 
resulted in a predicted DCS risk of 13%. This results in significant improvement in the work efficiency 
index defined as the total EVA time divided by the overall preparation time for EVA.  
Because DCS is expected to be mitigated to acceptable levels through the 8/32 environment in 
conjunction with a short-operational prebreathe protocol, the use of a variable pressure suit with the 
suitport on a vehicle like the MMSEV offers additional DCS mitigation capability. These include moving 
some traditional EVA work to the intravehicular activity (IVA) role, short EVA, single-person EVA, and 
immediate repress to 8 psia for DCS treatment and intermittent recompression [62] [63] [64] [65] [66]. 
Although all of these factors look to be reliable strategies for DCS mitigation, they need to be validated 
in human research studies. Because DCS mitigation is the primary driving factor for the 8/32 
environment, it is recommended that the first research efforts conducted by NASA validate that 
acceptable DCS risk will be achieved using this proposed environment. 
Exercise and Cardiovascular Performance 
Exercise Performance during Spaceflight 
Maintenance of exercise performance is of crucial importance for mobility of astronauts during long-
duration missions and upon return to 1-g. Despite crew allocation of about 2.5 hours per day to 
exercise, current exercise countermeasures are not fully effective in protecting against spaceflight-
induced decrements in muscle, cardiovascular function, and bone health. For example, ISS 
crewmembers (Expeditions 1 through 15, n = 18) demonstrated mean decreases in isokinetic knee 
extensor and flexor strength of 11% and 17%, respectively [67], 10% reductions in maximal aerobic 
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capacity [68], and 2% to 7% decreases (depending on site) in bone [69]. Recent analysis, including data 
from crewmembers with access to the advanced resistive exercise device (ARED), demonstrates that 
resistive exercise using ARED combined with adequate dietary intake has been even more effective in 
preserving bone mineral content and lean body mass [70]. It is now generally perceived that the current 
exercise countermeasures suite is effective at preserving muscle strength and aerobic performance if 
protocols are adhered to and adequate nutritional intake is maintained. There is a need to prevent 
spaceflight-related deconditioning to protect the health and mission readiness of current ISS crew as well 
as to enable NASA to protect fitness of longer-duration astronauts for moon, Mars, and NEO missions. 
Exercise Performance and Hypoxia 
Exposure to hypoxia is associated with a number of adaptive responses, which could act synergistically 
with microgravity to further impair muscle and exercise performance. Acutely, acclimatization to a 
moderate altitude, say 3,048 m (10,000 ft), takes approximately 3 weeks, during which time there is 
impairment in exercise performance due to decreased cardiac output, increased ventilation, and muscle 
fatigue [71] [72]. A decrease in the ability to perform exercise countermeasures early in flight may have 
negative consequences, as a large portion of the strength loss and muscle atrophy observed in ISS 
crewmembers may occur during the first few weeks in microgravity. Chronic exposure (> 3 weeks) to the 
8/32 environment may also magnify microgravity-induced changes in muscle and exercise performance. 
For example, exposure to moderate altitude accelerates muscle atrophy [73] and the transition from 
slow-to-fast twitch fiber type [74], decreases mitochondrial function and aerobic metabolism [75], and 
increases muscle fatigability [76]. Ultimately, there is a 0.5% reduction in aerobic power output per 100 
m (328 ft) of elevation [76] [77] [78] [79]. Moreover, similar to microgravity, individuals with higher 
aerobic capacity are more affected by hypoxic exposure [80], and there are gender differences in 
performance [81] [82] [83] as well. 
Cardiovascular System Performance and Spaceflight 
Alterations in cardiovascular function have been reported following both acute and chronic exposure to 
spaceflight and are thought to be secondary to circulatory unloading mediated by a central 
redistribution of fluid and an accompanied reduction in plasma volume. It is now accepted that these 
adjustments contribute to the increased risk of orthostatic intolerance and underlie the reduction in 
exercise capacity experienced by some astronauts. More recent studies using both ultrasound and 
cardiac magnetic resonance imaging have elucidated a number of structural and functional changes 
including left ventricular diastolic dysfunction, cardiac atrophy / remodeling (an average decrease of 
about 1 gram per week), and vascular / endothelial dysfunction, which is differentially altered between 
cerebral and peripheral vascular beds. 
Cardiovascular System Performance and Hypoxia 
The cardiovascular control systems are keenly sensitive to changes in both O2 and CO2. While there is no 
literature on the specific environment in question (8/32) combined with a stressor such as spaceflight, 
there is a relatively rich literature on the effects of hypoxia (including relatively mild hypoxia) here on 
Earth. A preliminary review of this literature revealed that chronic exposure to extreme HH such as that 
experienced at altitudes at or above 3,400 m (11,154 ft) may impart protective adaptive effects on the 
cardiovascular system. On the other hand, acute or intermittent exposure to such conditions, even at 
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altitudes that provide only modest hypoxia, may impart maladaptive responses. Specifically, Holloway, 
et al. demonstrated reduced left ventricular mass (about 11%) and impaired diastolic function in sea 
level dwelling subjects after only a short and gradual accent to the 5,300-m (17,388-ft) Mt. Everest Base 
Camp [84]. It was postulated that such changes were due to alterations in myocardial energetics, in 
particular reduced levels of phosphocreatine and adenosine triphosphate. Such results confirm and 
provide a mechanistic insight to an earlier finding by Kjaergaard and colleagues, who demonstrated that 
cardiovascular function was depressed even after only 18 hours of exposure to simulated hypoxia 
comparable to living at 4,000 m (13,123 ft) [85]. Papers by Nishimura [86] and Iwasaki [87] suggest that 
a relative altitude as low as 2,000 m (6,562 ft) is sufficient to alter vascular function in the brain in as 
little as 5 hours. 
It is likely that many of these effects are mediated, at least in part, by hypoxia-inducible factor 1 (HIF-1) 
[88] [89]. There is also evidence that HIF-1 interacts with reactive O2 species to form a positive feedback 
loop, thus exacerbating any oxidative stress already present during spaceflight. 
Exercise and Cardiovascular Performance Conclusion 
Acute and chronic exposure to the 8/32 environment may exacerbate microgravity-induced decrements 
in muscle and exercise performance. The relative impact of these changes is highly duration dependent. 
Acute studies are needed to compare muscle and cardiovascular performance at 8/32, probably using 
NH simulations to determine pre- and in-flight exercise prescriptions. Long-duration 8/32 exposure 
would prompt need for additional adaptation studies. 
Immune System 
We know that reactivation of latent herpes viruses occurs during short-duration spaceflights [90]. 
Recent data from the ISS indicate that in-flight dysregulation persists for the duration of a 6-month 
mission [91]. Thus, these data strongly suggest that spaceflight is associated with immune dysregulation. 
Therefore, persistent immune dysregulation leading to increased susceptibility to infections and 
reactivation of viruses as well as autoimmune manifestations might be a limiting factor for long-duration 
missions into deep space and constitute an unacceptable clinical risk for the crewmember’s health [92]. 
We also know that T cell function is impaired during hypoxic stress [93] [94], and that hypoxia promotes 
the accumulation of extracellular adenosine as a result of enhanced purine nucleotide degradation from 
adenosine tri- and diphosphate (ATP, ADP). Binding of adenosine to the cAMP-elevating Gs protein-
coupled A2 receptors results in an inhibition of effector functions of T cells and myeloid cells and 
includes the inhibition of expansion and secretion of cytotoxic molecules and cytokines [95]. This 
suppresses the immune system and thus renders the body more susceptible to infections, auto-immune 
manifestations and viral reactivations.  
The combined immune-suppressive effects of spaceflight environmental factors and even a short-term 
and rather mild hypoxic atmosphere is therefore of much concern. The spaceflight effects per se might 
be controllable even during long-term missions, but the additive and or synergistic effects of an 8/32 
hypoxic environment might render the risk of immune deficiencies less controllable. Thus, forward work 
investigating to what degree an additive and/or synergistic effect of the well-known spaceflight 
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environmental factors and 8/32 hypoxia occurs is highly recommended before planning for long-
duration deep space missions. 
Envisaged forward research for resolving this could constitute estimations of markers for immune function 
in 1) animal studies combining unloading with hypoxia for various durations, 2) tissue culture studies 
combining bioreactor rotations with hypoxia, 3) humans during bed rest studies combined with hypoxia, 
and 4) astronauts on the ISS combined with different levels of short and longer periods of hypoxia. 
Oxidative Stress and Damage 
There is evidence that spaceflight-induced oxidative stress and damage (OSaD) is a component of 
immune manifestations, decrease in bone and muscle strength, and development of the VIIP syndrome 
during spaceflight [96] [97] [98] [99] [100] [101] [102] [103] [104]. OSaD is the result of organic and 
systemic dysregulation of the free radical normalization and scavenging process, and is also the cause of 
many different manifestations of disease including atherosclerosis [105] [106] [107]. Therefore, during 
long-duration missions into deep space, OSaD could likely constitute a mechanism for development of 
cardiac disease [105] [108] [106] [109]. 
Changing the environment during spaceflight to an 8/32 environment will lead to hypoxia, which is 
known to further promote OSaD [110] [111]. The combination of spaceflight (radiation and 
weightlessness) and hypoxia will be a hazard that most probably will induce augmented synergistic and 
additive OSaD effects, thereby rendering immune dysfunction, bone demineralization, muscle 
degradation, and the VIIP syndrome less controllable – even with the use of the current 
countermeasures. Therefore, OSaD research is warranted before we know whether it is safe for the 
astronauts to change the vehicle environment to a lower O2 partial pressure during spaceflight [112] 
[113] [103]. Such research should be combined with the suggested research scenarios within the 
immune discipline. 
Nutrition and Bone 
Nutrition during Spaceflight 
In general, nutritional risks increase with duration of exposure to a closed food system and with 
countermeasure application designed for specific systems [114]. Inadequate nutrition can compromise 
crew health, leading to loss of bone and muscle mass and strength, altered immune system function, 
impaired cardiovascular performance, gastrointestinal function, endocrine function, oxidative defenses, 
ophthalmologic health, and psychological health and performance [114].  
Nutrition and Hypoxia 
One common effect observed with hypoxia exposure is anorexia. Acute effects of hypoxia at high 
altitude are anorexia, nausea, and vomiting [115]. Chronic effects are progressive weight loss [116]. Also 
supportive of this are the findings that low O2 availability in disease populations at sea level (i.e., 
respiratory diseases, chronic obstructive pulmonary disease) are associated with reduced energy intake 
and weight loss, and O2 supplementation can lead to weight gain in these populations [117]. 
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Several factors have been proposed to explain anorectic effects under hypoxic conditions. Homeostatic 
pathways dominate when energy stores are low and provide increased motivation to eat. Hedonic, or 
reward mechanisms, can override homeostatic mechanisms by increasing cravings and desires to eat 
highly palatable foods [118]. There is evidence that both of these mechanisms may be affected upon 
exposure to hypoxia [119] [120]. The hormones leptin and ghrelin play a role in the homeostatic 
pathway by regulating appetite. Leptin suppresses appetite and ghrelin stimulates the appetite. Plasma 
concentration of leptin and ghrelin were elevated and reduced, respectively, in high altitude 
acclimatized individuals (acclimatized at 3,675 m [12,057 ft] for 6 months), and the leptin correlated 
with food intake [120].  
There is also evidence that hypoxia can induce bone resorption processes [121] [122] [123] [124]. When 
bone resorption is increased, there is a potential increased risk for renal stones if bone formation is not 
concurrently increased. This is a significant concern, given concerns about renal stone risk and bone loss 
during spaceflight.  
Nutrition and Bone Conclusion  
If intermittent periods of hyperoxia and hypoxia are proposed for Exploration-class missions, then studies 
need to be conducted to determine how long anorexic effects would be expected. With intermittent 
exposures, a “plateau effect” regarding energy intake may not happen; consequently, crewmembers could 
lose more weight than expected. Maintaining body weight will be crucial for maintaining overall health in 
an Exploration-class mission. Bone mineral density and lean body mass can be maintained with proper 
resistive loads and adequate nutrition [125]. Studies also need to be conducted in these proposed 
environments to investigate renal stone risk and altered calcium metabolism.  
Behavioral Health and Human Performance Risks 
The following section examines the literature relating to the risk for behavioral health and performance 
decrements in a mildly hypoxic environment. These risks include behavioral, sleep, and team interaction 
effects. No studies were found that provided concrete evidence on the effects of a hypoxic environment on 
team dynamics at the 1,830 to 3,048 m (6,000 to 10,000 ft) range. Commonly reported psychological and 
behavioral changes resulting from the effects of hypoxia include susceptibility to AMS (discussed separately), 
loss of appetite (discussed in Nutrition and Bone section), an increase in anxiety, fatigue, psychomotor effects 
(with an increase in reaction time), and some implications for acclimatization and performance.  
Team 
Although no studies were found on team dynamics, there is evidence of high-performing teams in this 
altitude range. One clear example is mountain rescue teams, which  regularly perform high-stress, 
physically demanding and life-saving missions in this altitude range. As noted in conversations with the 
Rocky Mountain Rescue Group (Boulder, CO) operations director, rescue team members are also well 
acclimatized to this altitude, physically prepared, and experienced working in high physical and mental 
stress situations. These traits are most evident in mountain rescue teams with high, sustained mission 
counts . In addition to mountain rescue teams, Colorado-based professional sports teams show the 
capability of success in highly physically stressful environments. This includes two Super Bowl victories 
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for the Denver Broncos (1998 & 1999), two Stanley Cup championships for the Colorado Avalanche 
(1996 & 2001), and a  National League pennant for the Colorado Rockies (2007). 
Anxiety 
Few studies examined the incidence of anxiety symptoms in the 1,830 to 3,048 m (6,000 to 10,000 ft) 
range; most studies were conducted at higher altitudes. At a simulated altitude of 3,500 m (11,483 ft), 
Bushov, et al. evaluated personality factors in mountaineers and nonmountaineers. It was observed that 
neuroticism levels were lower in mountaineers, moderated by the physical adaptation to altitude [126]. 
These reduced levels of neuroticism correlated with reduced levels in the symptoms of AMS and may 
have implications for astronaut selection. Additionally, Bushov, et al. concluded that the influence of 
anxiety under hypoxia is only exerted on stimulus-response tasks but not on more complex cognitive or 
psychomotor tasks [126]. Virues-Ortega, et al. [127] proposes a more complex interaction with the 
effect of personality traits associated with anxiety (emotional stability, anxiety trait, neuroticism) and 
differences in the hypoxic ventilatory response as individual differences that affect the effects of altitude 
exposure. Emotional stability is associated with better adaptation to altitude in regard to fatigue and 
AMS symptoms. However, only limited research is available, and it would be worth looking at this in an 
operational spaceflight context. 
Fatigue 
Martin, et al. [128] describe fatigue as any level of exercise at altitude that represents a greater “work 
intensity” when compared with that at sea level. High and extreme altitude studies have found negative 
correlations between fatigue and emotional stability [129]. No studies were found for the 1,830 to 
3,048-m (6,000 to 10,000-ft) altitudes. Higher levels of fatigue are likely to exacerbate hypoxia 
symptoms and could potentially lead to long-term effects, though this remains a question for future 
investigations [127]. 
Psychomotor 
Most psychomotor studies have been conducted at very high altitudes (6,000 to 8,000 m) (19,685 to 
26,247 ft), and there is a lack of consensus on the initial cause of psychomotor effects. It has been 
argued that psychomotor effects could be due to related factors of hypoxia (such as anxiety and fatigue) 
instead of a direct result of the hypoxic environment. The minimum height that produces motor 
impairments varies among investigations between 2,500 and 6,000 m (8,202 and 19,685 ft). In addition, 
consensus for tasks and protocols to detect motor impairments is necessary (e.g., Purdue Pegboard 
versus the Finger Tapping Task) [127].  
The effect that is most accepted in altitude literature is the increase in complex reaction time (CRT). CRT 
has been found to be a sensitive index of acute altitude exposure both in laboratory conditions [130] 
[131] and real expeditions [132] both with and without AMS [133], although most effects do not appear 
before 6,000 m (19,685 ft). After prolonged exposure, significant increase in CRT can be found above 
2,500 m (8,202 ft) [134] [135]. Denison, et al. found an increase in CRT in altitude as low as 1,500 m 
(4,921 ft) [136]. Fowler, et al. demonstrated a significant increase in CRT in subjects at altitude of 2,438 
m (8,000 ft) [131]. Abraini, et al. [137] and Bouquet, et al. [138] show that basic motor processes at high 
altitudes remain unaffected.  
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Perception 
Few studies have been conducted on perception in the 1,830 to 3,048-m (6,000 to 10,000-ft) range; most 
have mostly been conducted at high and extremely high altitudes. Altitude simulations at 1200, 2400, and 
3700 m (3937, 7874, and 12139 ft) by Watson, et al. [139] observed that event-related potentials (the 
resulting brain response from a sensory, cognitive, or motor event) and increase of reaction time were not 
associated with a rise in the absolute threshold for auditory stimuli up to 16 kHz. Fowler and Grant 
obtained similar results [140]. Burkett and Perrin noticed no effects on the discrimination of speech 
sounds at 6,600 m (21,653 ft) [141]. Finally, in an analogous investigation, Martin, et al. [128] found no 
effects on the localization of stimuli at an altitude of 3,700 m (12,139 ft). Alterations in perception of 
brightness and  color have been reported at higher altitudes (3,962 m, 4,300 m) (13,000 ft, 14,107 ft) 
remaining throughout a stay at altitude [142] [143]. Ground-based analog studies could confirm that no 
effects are expected in auditory perception, discriminations of speech sounds or localization of stimuli and 
could examine the threshold for changes in brightness and color perception.  
Cognition, Memory and Attention 
Sensitivity of brain structures to hypoxia indicates that exposure to altitude has the potential to cause 
dysfunctions to learning and memory. Numerous high altitude and extreme altitude studies have 
validated this hypothesis. Research supports that memory difficulties depend on a reduced capacity to 
learn new information rather than its retrieval [144] [145] [146]. At lower altitudes, conflicting evidence 
is found. Subjects exposed to a simulated altitude of 2,438 m (8,000 ft) performed a card-sorting task 
faster [147]. At the altitudes in question (1,830 to 3,048 m [6,000 to 10,000 ft]), alterations in long-term 
memory, specifically episodic memory, have rarely been observed, and always as an acute effect, never 
as long-term effect [127].  
Both animal and human observations conclude the lower threshold of altitude needed to produce 
spatial memory dysfunction is above 3,500 m (11,483 ft) [148] [149].  
Altitude effects on attention capacity are rarely described in altitude literature. Some impairment was 
found in subjects at 4,200 m (13,780 ft) using the Digit Symbol test from the Wechsler Adult Intelligence 
Scale [150]. Reductions in cognitive flexibility and resistance to interference have been recorded several 
times above 2,500 m (8,202 ft) [127]. As previously noted, however, these decrements could be related 
to anxiety or fatigue. 
Neural Structural Changes 
Neuropsychological impairment are said to be the result of respiratory, circulatory, and brain detriments 
in adaptation to hypoxic environments. Some brain structures are more dependent on O2 supply than 
others, including the hippocampus, and the parahippocampal region (surrounding temporal lobe 
region). These structures are involved in conscious recollection and memory, and the temporal lobe is 
involved in familiarity-based discrimination. These structures would be most affected during 
acclimatization to the 8/32 environment during spaceflight.  
Schulze, et al. observed that exposing his subjects to an O2 saturation (SaO2) between 88% and 90% 
(2,500 m [8,202 ft]) produced a metabolic delay in the hippocampus, hypothalamus, cortex, and 
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striatum [151]. These effects have implications for multiple brain functions. The hippocampus is 
important for spatial memory, short- and long-term memory, the hypothalamus controls the endocrine 
system that regulates body temperature, fatigue, hunger, thirst, sleep, and circadian cycles, the striatum 
is linked to planning and modulation of movement pathways and executive function, and the cortex is 
related to memory, attention, perceptual awareness, thought, language, and consciousness [152]. 
Gozal, et al. used immunohistochemistry to record an increase in programmed cell death (apoptosis) in 
area CA1 of the hippocampus after 2 days of exposure to intermittent hypoxia (10 psi / 21% O2, EAA = 
3,132 m [10,275 ft]) [153]. After 2 weeks, the alteration reverted. It is important to examine the 
postflight effects to determine the time necessary to return to baseline. 
Behavioral Health and Human Performance Conclusion 
The findings showed that the effects of the 8/32 environment will have short-term behavioral and 
performance impacts. Adaptation can occur within 3 days in most cases [54], and the impacts are not 
expected to be severe enough to compromise a mission, although further study may be needed. Mitigation 
strategies can be developed to minimize the increased risk of performance and health decrements. 
The degree of decrements in the microgravity environment is unknown, as they are subject to many 
factors (individual / genetic variations, environmental effects, workload, duration of exposure, etc.). 
Further studies would be beneficial to establish a baseline for these under high-fidelity mission 
operational constraints, and to develop and validate mitigation strategies.  
Sleep  
The introduction of an 8/32 environment may have implications for sleep in microgravity. In particular, 
difficulties in sleep are anticipated in hypoxic environments during the acclimatization phase.  
Sleep during Spaceflight 
Sleep deprivation is associated with degraded performance of neurobehavioral tasks, as well as 
decrements in health and well-being; hence, any stressor that has the potential to affect the quality of 
sleep during a mission could be detrimental to the astronaut. Studies have shown that sleep is reduced 
with an average nightly duration of 6 hours in short-duration missions (i.e., Space Shuttle), despite 
schedule requirements that accommodate 8 hours of sleep per night [19] [154]. Duration may not be the 
only aspect of sleep that is affected currently in spaceflight. Shuttle astronauts reported poor sleep quality 
on orbit [17]. Few studies have objectively looked at sleep structure in space, but those that have 
evaluated sleep stages have found changes, although these studies have included only a small number of 
participants [154] [155]. Ground research demonstrates that changes in sleep structure are associated 
with health and performance decrements [154] [155] [156] [157]. Reduced sleep and possibly altered 
sleep structure already poses implications for cognition, alertness, and performance on critical tasks.  
Sleep and Hypoxia 
Terrestrial studies indicate that hypoxic environments can yield similar detriments to sleep as what has 
been seen in the spaceflight environment, particularly field studies that include high workload and 
increased exertion. Hence, the combination of adding a hypoxic environment to existing stressors of 
sleep in space could potentially exacerbate negative effects. 
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The lowest altitude at which sleep and/or post-sleep performance are affected is not definitively known. 
Decreased quality of sleep has been reported after acute ascent to altitudes of North American ski 
resorts (2,000 to 3,000 m) (6,561 to 9,843 ft) and higher. Changes in sleep architecture include a shift 
toward lighter sleep stages, with marked decrements in slow-wave sleep and with variable decreases in 
rapid-eye movement sleep [158]. Accordingly, sleep at these altitudes was perceived as poor quality 
with the sensation of occasional awakenings, a sense of suffocation caused by periodic breathing 
relieved by a few deep breaths, and resumption of sleep.  
Weil proposes respiratory periodicity (arousals) at altitude results from alternating respiratory 
stimulation by hypoxia and subsequent inhibition by hyperventilation-induced hypocapnia [158]. 
Despite relatively the same sleep duration, upon arising from sleep, subjects reported impressions of 
greatly abbreviated and restless sleep. Also, during wakefulness, subjects experience drowsiness [158]. 
This relationship may need further evaluation because CO2 levels are several times greater on the ISS 
than on Earth [13]. 
Studies in simulated environments, however, found less conclusive effects on sleep and related outcomes. 
Muhm, et al. studied post-sleep neurobehavioral performance decrements at simulated 2,438 m (8,000 ft) 
on O2 saturation, heart rate, sleep quantity, sleep quality, post-sleep neurobehavioral performance, and 
mood [159]. Results showed SaO2 before sleep was significantly lower at altitude than at sea level. During 
sleep, SpO2 decreased further at both altitude and ground. SaO2 was below 90%, 44.4% of the time at 
altitude and 0.1% of the time at sea level. Subjects participated in three 18-hour sessions and sleep was 
more disturbed in the first study session than in subsequent sessions (potentially an argument for pre-
adaptation before flight), and older subjects had more disturbed sleep. Despite these findings, objective 
and subjective measurements of sleep quantity and quality did not differ significantly with altitude, nor 
post sleep, neurobehavioral performance, or mood.  
Thomas, et al. found that sleep at simulated 3,962 m (13,000 ft) was not associated with decrements in 
working memory or simple reaction time in healthy non-smoking men and women [160]. Weiss, et al. 
found no difference after hypoxia in sleepiness, encoding, verbal learning, objective vigilance, attention, 
or working memory at the same altitude with intermittent 9-hour exposures for 28 consecutive nights 
[161]. While these results were unexpected, they highlight the limitations of simulated studies, possibly 
because they lack the conditions of high workload and exertion found in field studies and the spaceflight 
environment.  
Space Radiation  
The Space Radiation Program is focused on research to accurately define, quantify, and mitigate the 
health risks associated with exposure to high-charge, high-energy galactic cosmic rays and solar protons 
that are not found on Earth. Of concern are the risks of radiation carcinogenesis, acute or late central 
nervous system effects, degenerative tissue effects (including circulatory diseases, stroke, and cataract) 
and the acute radiation syndrome due to solar particle events. At the cell and molecular level, radiation 
causes genetic damage by two methods, through direct energy transfer to DNA molecules leading to 
base damage or strand breakage, and indirectly through free radical mediated pathways that cause 
chemical damage to the DNA molecule. Low-linear energy transfer (LET) radiation, such as gamma or x-
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rays found on Earth, mediate much of their damaging impact through indirect mechanisms, whereas 
high-LET radiation (galactic cosmic rays) found in the space radiation environment form densely ionizing 
tracks as they traverse a cell and lead to direct DNA damage [162].  
The impact of O2 in modulating the effectiveness of radiation for inducing cellular damage is well 
documented and is dependent on the type or quality of radiation, radiation dose, and dose-rate. The 
level of cellular O2 present during radiation exposure can amplify the generation of radicals and alter the 
resolution of chemical damage to cellular biomolecules, including DNA. This is known as O2 
enhancement and is expressed as the O2 enhancement ratio (radiation dose required to cause effect 
without O2/dose required to cause effect with O2, which stems from the ability of O2 to promote the 
biological damage of low-LET radiation caused by free radicals. Tissues are less sensitive to the effects of 
radiation when in a hypoxic or anoxic state, and in the context of a tumor, this effect is directly 
associated with radiotherapy failure [163]. O2 enhancement is diminished at low dose and lower dose-
rates of radiation exposure, such as those that may be encountered during space travel, and is greatly 
diminished or lacking for high-LET radiation where the direct effects of radiation on DNA double-strand 
breaks dominate [164] [165]. Based on these studies, it is not anticipated that there will be any 
significant impact on the radiation risk portfolio due to the slight hypoxia that may be associated with 
the 8/32 environment proposed for exploration vehicles and, therefore, this would not be considered 
high priority at this time. In addition, no obvious factors that would alter the Space Radiation risk profile 
were identified in a review of relevant epidemiology data assessing the long-term impact of living at 
high altitude, which is the closest Earth-based analog for this type of environment.  
The proposed 8/32 exploration environment is best approximated by high altitude environments on 
Earth with an equivalent air altitude in the range of 1,981 to 2,896 m (6,500 to 9,500 ft). A large amount 
of literature exists regarding the acute effects of high altitude on human physiology. Multiple 
epidemiology studies analyze the chronic health implications of living at high altitude, and many analyze 
effects on the cardiovascular system and cancer – risks of concern for space radiation [166] [167]. 
Because of multiple confounding factors, these studies are generally controversial and should be 
interpreted with caution. We reviewed several of these studies that showed a protective effect of living 
at high altitude on mortality from cardiovascular disease. The first study, from German Swiss citizens 
[168], shows a decreasing mortality due to stroke and coronary heart disease with increasing altitudes 
from 259 to 1,960 m (850 to 6,430 ft). A similar effect was seen in a second, recent study [169] where 
the relationship between altitude, life expectancy, and mortality for leading causes of death in the 
continental United States were analyzed. Here, altitude was inversely correlated with mortality from 
ischemic heart disease, but detrimental for chronic obstructive pulmonary disease, with no significant 
association with life expectancy, cancer, or stroke. The authors of the second study conclude that this 
protective effect is not related to changes in the classic risk factor for these diseases but may be 
attributable to an overall enhancement in cardiac efficiency and changes at the molecular level that may 
offer protective effects, such as the hypoxia-associated changes in hemoglobin and iron metabolism. 
Finally, we found one study conducted in the United States where the risk of cancer was inversely 
correlated with geographical elevation [167]. This study also found a significant decrease in mortality 
due to heart disease at higher elevations, although they did not control for known risk factors related to 
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diet and smoking. Of note is the fact that background levels of radiation are higher at increasing altitude 
due to diminishing shielding effects of the atmosphere; therefore, the interplay of complex factors must 
be considered in deciphering these results. Overall, we assume that changes in physiologic O2 levels in 
the proposed exploration environment will be minimal and are not likely to significantly alter biological 
damage caused by low dose-rate space radiation and, therefore, are not likely to change the risk profile 
of the Space Radiation Program.  
Exploration Medical Capability 
HRP has assigned the Exploration Medical Capability (ExMC) Element the responsibility of addressing the 
overarching risk of unacceptable health and mission outcomes due to limitations of in-flight medical 
capabilities. A long-term change in atmosphere impacts ExMC’s stance toward exploration risks and 
primarily affects Gaps 1.01: inadequate information on preflight medical screening capabilities for 
exploration class missions, 2.01: limited knowledge about incidence rates, probabilities, and 
consequences relative to loss of crew and/or loss of mission for the medical conditions on the Space 
Medicine Exploration Condition List (SMEMCL; JSC-65722), 4.04: lack of hardware for variable O2 
delivery that minimizes localized O2 build-up. 
The SMEMCL was created to define the set of medical conditions that are most likely to occur during any 
exploration DRM as the first step in addressing the aforementioned risk. The list was derived from the 
ISS Integrated Medical Group Medical Checklist (JSC-48522), the Flight Data File Medical Checklist (JSC-
48031), in-flight medical incidence data in the Lifetime Surveillance of Astronaut Health (LSAH) 
repository, and NASA flight surgeon subject matter expertise. The list of conditions was prioritized for 
specific DRMs with the assistance of the ExMC Advisory Group, which is composed of flight surgeons 
and representatives from Space Medicine management, the astronaut office, the National Space 
Biomedical Research Institute (NSBRI), and inputted incidence data from the Integrated Medical Model 
(IMM) that is further described.  
The purpose of the SMEMCL is to serve as an evidence-based foundation in determining which medical 
conditions could affect a crewmember during a given mission profile, which of those conditions would 
be of concern and require treatment, and for which conditions a gap in knowledge or technology 
development exists. This information will be used to focus research efforts and technology 
development. Atmospheric changes from sea level to 8 psi and 32% O2 will change the incidence of 
diseases currently being researched such as AMS, add new diseases to consider such as chronic 
mountain sickness, and alter the diagnosis and treatment of diseases not directly induced by hypoxia 
such as a pneumothorax that needs increased O2 for treatment. Gap 1.01 will be affected by the 
changing disease risk and requires a reevaluation of screening capabilities for AMS to ensure that 
crewmembers can tolerate long-duration missions. 
The IMM addresses Gap 2.01 and is a stochastic model that uses Monte Carlo methodology to simulate 
medical events and estimate the impact of these medical events for a given DRM. Outcomes include 
Crew Health Index (CHI), probability of evacuation (EVAC), and probability of loss of crew life (LOCL). 
20,000 trials are simulated for each DRM and probability distributions for CHI, EVAC, and LOCL are 
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determined. Thus, a change in cabin pressure will directly affect diseases such as AMS and DCS, but also 
affect the consequence of O2-dependent diseases such as respiratory infection and anemia. 
Treatment of these O2 -dependent diseases requires directed delivery of concentrated O2, which is being 
researched and developed by ExMC to close Gap 4.04. This capability may be impaired by a lower 
ambient cabin pressure and higher O2 concentration, requiring a reevaluation of current efforts. 
Though none of these concerns would preclude a change to an 8/32 environment, further research 
would help characterize the effect of this change on ExMC’s Gaps and concerns. An experimental study, 
placing cohorts in an 8/32 environment, with sufficient power to be statistically significant, would 
provide valuable data about susceptibility to this environment, incidence of disease, and effectiveness of 
treatment modalities. Results from such a study would provide valuable input into IMM and allow for 
treatment testing and O2 delivery. 
Overall Synergistic Effects of 8/32 and Spaceflight Environment 
The combination of hypoxia, hypobaria, and hypogravity can potentially worsen the physiologic changes 
due to these environments that have been described separately in the literature. To our knowledge, no 
data exist on the combination of all three environments, or hypobaria combined with hypogravity. 
Physiologic changes to HH and hypoxia combined simulated microgravity (head-down bed rest) 
described in the literature are summarized in Table 4.  
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Table 4. Physiologic Changes in Response to Hypoxia Combined With Hypobaria and Hypoxia 
Combined with Hypogravity 
 Hypoxia + Hypobaria Hypoxia + Hypogravity 
CNS/Ocular Acute mountain sickness 
(headache, nausea, weakness, 
fatigue, dizziness, difficulty 
sleeping) [192] 
Acute mountain sickness 
symptoms when exposed to 
hypoxia and head-down bed rest 
[170] 
Minor reduction in cerebral blood 
flow and resistance with 
combination [194] 
Cardiovascular Systemic vasoconstriction [196] 
[193] 
Increased blood pressure [193] 
[195] 
Increased heart rate [193] [195] 
[197] 
Decreased stroke volume [193] 
Decreased cardiac output [193] 
Decreased maximal O2 
consumption (VO2max) exercise 
performance [193] 
Reduced VO2max but may be due 
to inactivity of bed rest [170] 
Possible small improvement in 
orthostatic tolerance [170] 
Respiratory Pulmonary vasoconstriction [195] 
[197] 
Increased respiratory drive  [193] 
Increased pulmonary blood 
pressure [193] 
No significant change in pulmonary 
mechanics and gas exchange 
compared to hypoxia alone [170] 
Hematological/Immunological Reduced plasma volume [193] 
[197] 
Increased hematocrit [193] 
Increased erythropoiesis [193] 
[197] [190] 
Polycythemia [196] 
Increased blood viscosity  [193] 
Increased thrombotic risk [190] 
No significant change in 
hemoglobin, hematocrit, plasma 
fibrinogen, and plasma albumin 
compared to hypoxia alone [170] 
Cognitive Variable impairment on 
performance [193] 
No significant difference in 
arithmetic, short-term memory, 
and maze tracing [170] 
Nutritional Reduced appetite, energy intake, 
and body mass irrespective of 
acute mountain sickness [191] 
No articles found 
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Whereas some of these changes act in opposite ways, other changes may be synergistic. For example, 
Loeppky, et al. [170] found that subjects exposed to hypoxia (1,645 m [5,400 ft]) and -5° head-down bed 
rest had AMS symptoms, whereas subjects exposed to hypoxia only remained asymptomatic, suggesting 
an additive effect between hypoxia and reduced gravity. However, the same study found a small 
improvement in orthostatic tolerance attributed to increased plasma norepinephrine.  
Clearly, much more research is needed. Without research and experience operating in a combined 
environment, predictions of physiologic changes from the combination of the 8/32 environment with 
the spaceflight environment will be very limited since no known data exist. 
Furthermore, if exploration crews are to be exposed to similar CO2 levels as the ISS, the effect of 
hypercapnia combined with HH in hypogravity will also need to be researched. CO2 alone has 
widespread effects on human physiology, including: 
 Altering O2 binding: CO2 causes a rightward shift of the oxyhemoglobin saturation curve, so that 
at a given ppO2, less O2 is bound to hemoglobin, resulting in worsened hypoxia especially during 
exercise or if a patient is in shock when O2 demand is increased.  
 Stimulating ventilatory response: CO2 not only increases minute volume and respiratory rate in 
the short term, but it also appears to alter the pH and CO2-dependent set point for respiratory 
drive after chronic exposure to CO2 [14].  
 Cerebral vasodilation: CO2 is a potent cerebral vasodilator and is linked to elevated intracranial 
pressure. Silwka [171] measured cerebral blood flow (CBF) at the middle cerebral artery in healthy 
subjects exposed to 0.7% and 1.2% CO2 environments for more than 23 days and found that CBF 
increased by as much as 35%; moreover, CBF did not return to baseline post-exposure. This 
persistence post-exposure is similar to the persistence of elevated intracranial pressure in some of 
the symptomatic astronauts who were subsequently diagnosed with VIIP, suggesting that CO2 may 
play a contributory or exacerbating role in the VIIP syndrome in long-duration spaceflight. 
 Altered bone homeostasis: CO2 exposure results in a respiratory acidosis that appears to be 
compensated by the kidneys at higher levels (> 3% CO2) and by the bone at lower levels (0.5 to 
1.5% CO2) [172]. The bone, which contains a large reserve of the body’s bicarbonate and calcium 
carbonate, serves as a buffer for acidosis; chronic acidosis can result in the release of calcium 
carbonate and bone breakdown [14]. In addition, chronic acidosis is associated with cell-mediated 
bone resorption and increased urinary calcium excretion due to stimulated osteoclastic activity 
and suppressed osteoblastic activity [123] [173] [174]. Thus, there is concern about chronic 
hypercapnia exacerbating an astronaut’s risk of developing kidney stones. 
 Behavioral health and performance: Anecdotally, ISS crewmembers have been noted by ground 
controllers to be more irritable or lethargic when they are gathered in a small module for public 
affairs events, presumably due to local accumulation of CO2. Terrestrially, mild visuomotor 
impairment has been observed in subjects exposed to 1.2% CO2 [175]. Additionally, there 
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appears to be a dose-response relationship between CO2 level and symptoms such as nausea, 
dizziness, derealization, fear of losing control, and paresthesia [176]. 
8/32 EVA Considerations 
The purpose of the 8/32 environment is to facilitate a high efficiency EVA capability for NASA. Current 
EVA preparation protocols from the Earth normal ISS atmosphere take a minimum of 4.5 to 5 hours 
before a crewmember begins an EVA. This long preparation time leads to a limited number of longer 
EVAs. Short EVAs are impractical and single-person EVAs would be unsafe because there would be no 
rescue capability. Improved efficiencies with suit preparation and checkout may reduce this time, but 
not dramatically. The risk of injury and impaired performance during EVA is directly related to the time 
spent in the EVA suit, so any operational concept that maintains EVA efficiency and productivity while 
minimizing time spent in the suit would be the most effective solution for an Exploration Program with 
heavy EVA needs.  
General Medical Concerns about Frequent EVAs 
Given the main motivation behind a reduced environment such as 8/32 is to facilitate frequent EVAs, 
several general concerns about frequent EVAs are discussed here.  
First, repeated cycling between suit pressure and habitable volume pressure could have detrimental 
effects on the crew. Intermittent hypoxia, defined as repeated episodes of hypoxia interspersed with 
episodes of normoxia, has been studied to enhance exercise performance in athletes, since the so-called 
“live high and train low” method can stimulate erythropoietin and red blood cell production and 
increase ventilation [177]. However, intermittent hypoxia is also associated with increased arterial blood 
pressure through activation of the renin-angiotensin system in healthy subjects [178] and enhanced 
sympathetic and blood pressure responses to acute hypoxia and hypercapnia [177]. Cumulative 
exposure to intermittent hypoxia may produce progressive brain injury and subsequent neurological 
impairment due to metabolic stresses and reactive free radicals during hypoxia [177]. Intermittent 
hypoxia appears to elicit the same ventilatory changes to hypoxia as chronic hypoxia [179]. 
Furthermore, patients with obstructive sleep apnea, who serve as a model for chronic intermittent 
hypoxia, have a high risk of cardiovascular disease, increased levels of inflammatory markers, oxidative 
stress, coagulation, and thrombosis [180] [181].  
Second, EVAs by nature are strenuous activities, and musculoskeletal injuries are more likely as the 
number and frequency of EVAs increase. The current extravehicular mobility unit (EMU) has long been 
associated with shoulder injuries and fingernail delamination; the former is believed to be due to 
scapulothoracic restriction imposed by the planar hard upper torso (HUT) of the EMU. Astronauts have 
also been injured while donning or doffing the EMU due to the awkward arm and shoulder movements 
required to maneuver around the HUT and scye bearings [182]. Efforts to design new spacesuits for 
exploration are attempting to capture the lessons learned from the Shuttle-era EMU, with such 
innovations as a quick donning rear-entry suit. However, even the ideal spacesuit will likely require the 
astronauts to work against a pressure differential of 4.3 psi or greater, thus imposing a risk of 
musculoskeletal wear and tear over time. The more the astronauts work inside a pressurized suit, the 
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more likely they will sustain contusions, sprains, strains, and general musculoskeletal pain. The latter 
could mask or be mistaken for type I DCS, predisposing astronauts to more serious DCS or unnecessarily 
requiring hyperbaric treatment. 
Third, ISS experience has shown that crew well-being and mental health are significantly influenced by 
the operational tempo and a balanced work-rest schedule. The longer exploration missions will require 
the same “marathon” mentality as the ISS compared to the Space Shuttle Program’s “sprint” mentality. 
Activities such as EVA, science, spacecraft maintenance, and public outreach will compete for the 
crewmembers’ time, while daily time for meals, exercise, hygiene, and relaxation must be preserved. 
Behavioral Health Implications for an EVA-Intensive Mission 
Anecdotal comments from Jack Stuster’s review of astronaut journals highlight the heightened level of 
importance and increased stress felt regarding EVAs [183]: 
 “I was pretty exhausted mentally after the EVA, but felt pretty good physically overall” 
 “Today is EVA day. I’m starting to have that I-think-I-must-be-forgetting-something feeling.” 
 “It seems like the EVA stuff bonds folks. We feel each other’s pain and understand the hardships 
associated with what we are doing.”  
 “After our EVAs were over, we had a day and a half off. It was one of the first times in which we 
had some time off 2 days in a row during the missions, so we planned dinner and a movie 
night.” 
Currently, EVAs are some of the most grueling and physically and mentally demanding activities required 
during a space mission. On EVA day, the schedule only accommodates the time for EVA, and the EVA 
astronaut is not required to exercise or complete other tasks. 
Evidence indicates that sleep is significantly reduced during the time before an EVA [19]. Before an EVA, 
it is common for crewmembers to be too “wired” to sleep [17]. General practice has been not to 
schedule 2 consecutive days of EVA unless resources are limited. The proposed mission scenario with 
EVA every day or every other day can result in a heightened stress response, reduced sleep, and/or 
interrupted sleep in addition to the already reduced sleep in microgravity. This could have implications 
for task performance, memory, cognition etc. 
During EVAs, the crew is especially vulnerable to the space environment. A dramatic shift in the 
perception of the mission will happen during an EVA-heavy mission, where astronauts will routinely 
expose themselves to an especially harsh and physically and mentally stressful environment. Increased 
training, mental preparation and safety vigilance will be necessary for this, and may have implications 
for selection as well.  
Decreased Risk of Injury and Impaired Performance during EVA 
Most of the mitigations that reduce DCS risk also apply to the reduction of injury and impaired 
performance during EVA. Moving traditional EVA work to the IVA role, short EVAs and single-person 
EVAs are all made possible by the 8/32 environment in conjunction with the MMSEV. Desert Research 
and Technology Studies (DRATS) in 2008 compared EVA performance for two-suited crewmembers in an 
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unpressurized rover (UPR) versus the same crew with a pressurized rover (MMSEV) using suitports and 
EVA suits as needed to complete mission objectives. Comparing a 1-day traverse in both conditions, the 
MMSEV condition showed a 31% increase in 1-day traverse distance, 57% increase in total productivity, 
470% increase in productivity per EVA hour, 23% increase in boots-on-surface EVA time with a 61% 
decrease in total EVA time, decreased fatigue, and decreased discomfort [184].  
The operational concepts enabled by the 8/32 environment allow significant EVA capability without 
unnecessary time spent in the suit. Less time in the suit also reduces the overall probability of injury. 
Strauss reported a likelihood of a crewmember reporting some medical symptom at 24.6% per Neutral 
Buoyancy Laboratory training session [185]. Scheuring, et al. reported a very similar likelihood of a 
minor injury at 0.24 per EVA [186]. Although these symptoms/injuries ranged from minor to significant, 
it is still a very high reporting rate and indicates that more effort needs to be focused on injury 
mitigation, human performance optimization, and increased EVA efficiency by moving some traditional 
EVA tasks into the IVA environment.  
8/32 Pressure Mediated Considerations 
Not all of the potential human issues from the 8/32 environment are related to the addition of mild 
hypoxia. Some of the hardware used by the astronauts is pressure sensitive. This section will discuss 
issues pertaining to operations at 8 psia irrespective of the FIO2.  
Increased Insensible Water Loss 
This is a well-known aspect of mountaineering due to several factors including humidity, temperature, 
and pressure differences at altitude, but there is evidence that a reduction in pressure alone will 
account for an increased insensible water loss that will need to be replaced with additional drinking 
water [187]. This increased water loss will also need to be considered by the ECLSS team. 
Advanced Food Technology 
The Advanced Food Technology (AFT) project team is investigating the possibility of a partially 
bioregenerative food system on the Martian surface or any other extended surface mission. Fresh fruits 
and vegetables and possibly other commodities can be grown hydroponically in environmentally 
controlled chambers. Other raw commodities can be launched from Earth in bulk and processed into 
edible ingredients. These processed ingredients along with the fresh fruits and vegetables and other 
packaged foods and ingredients can be used to prepare the meals in a galley. It is expected that due to 
“return on investment,” this concept of operations would not occur until a surface habitat is in continual 
operation for multiple years.  
The 8/32 environment can affect operations during a surface mission where food processing (converting 
raw ingredients such as soybeans into tofu) or food preparation beyond simple heating and rehydration 
is conducted. At reduced pressure conditions, water boils at much lower temperatures, which slows the 
heat transfer into the food in the water. The combination of hypogravity and lower pressure may 
improve colloidal stability, but mixing, fluid transport, boiling, condensation, and natural convection are 
all processes likely to be affected negatively by the reduction in gravity. Thus, any equipment evaluation 
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must consider whether the equipment depends on physical phenomena that fail to exist in a 
hypogravity or hypobaric environment like Mars. At reduced pressure conditions, water boils at much 
lower temperatures, which slows the heat transfer into the food in the water. At that pressure, the 
boiling temperature for water is 84°C (183°F). To create safe and acceptable food, cooking and 
processing of food is dependent on time/temperature combinations. Also, certain resulting textures 
come from cooking. For example, if the starch in rice is not gelatinized at 83°C (181oF), then the rubbery 
texture is replaced by dry, granular textures. The AFT team has not conducted any tests at 8 psi, so there 
are no data on what would be required on the surface. A solution may be to use a pressure cooker, but 
that requires extra mass and volume and may not be the answer to all “cooking.” Understanding the 
physical changes in the environment and the impact to food preparation and processing is critical to 
estimate the microbial load throughout the cook, quantify the risk of foodborne illness, and reduce the 
risk to acceptable levels.  
A major research thrust for AFT is identifying a high O2 barrier packaging material. Oxidation in food 
results in quality loss including nutrient breakdown and color and flavor changes. There is actually a 
potential advantage to the 8/32 environment because there would be less O2 to deteriorate the food. A 
technology gap would be what degree does the 8/32 environment affect product quality and whether 
the packaging barrier requirements would be modified significantly.  
Acoustics 
The 8 psia environment might affect acoustics. There is an assumption that lower atmospheric pressure 
in a habitat will reduce the sound intensity of both noise and voice. For example, lower pressures are 
expected to necessitate higher air flow rate through the ECLSS, resulting in increased fan noise, which is 
countered by noise transmission in a thinner air. The balance between several factors related to 
acoustics is unknown since there can be off-setting effects. At a lower pressure, the acoustic radiation 
efficiency is reduced, so noise levels should be lower in general. However, it will be more difficult to 
project your voice. For voice communications, these are off-setting each other and the net effect is 
unknown. There may be an additional effect in hearing (there is with microphone response), which 
would likely require some further investigation, starting with a literature review and followed, if 
warranted, by some additional studies.  
Crew Health Care Systems 
An Exploration equivalent to the ISS Crew Health Care System (CHeCS) will consist of countermeasures, 
environmental health monitoring, and health maintenance. The impact of an 8/32 environment will 
have to be evaluated in terms of each of these elements. 
The Countermeasures System (CMS) will provide aerobic and anaerobic exercise capabilities for 
crewmembers to minimize cardiovascular deconditioning, bone loss, and muscle atrophy due to disuse 
in microgravity. In general, the current CMS on the ISS are believed to be adequate in maintaining 
aerobic fitness and bone mineral density (although preservation of bone architecture is still being 
debated). However, CMS hardware may be reduced in exploration missions given a smaller habitable 
volume compared to the ISS. An 8/32 specific concern is that air pressure-dependent hardware such as 
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the ARED would work less effectively, requiring more mass and/or more frequent cylinder evacuations 
to maintain the same range of resistance. 
Exercise protocols of lower intensity or shorter duration [15] have been proposed for an 8/32 
environment, to preserve consumables and minimize hardware cycling, while reducing the risk of AMS, 
as exercise has been associated with more severe AMS symptoms at simulated altitude [52]. However, 
these potential benefits of reduced exercise protocols must be weighed against the risks of 
cardiovascular and musculoskeletal deconditioning in terms of ability to perform strenuous mission 
tasks (e.g., EVA) and long-term health consequences. 
The Environmental Health System (EHS) will enable the monitoring of air and water quality, toxicology, 
radiation, and acoustics in the spacecraft. Generally speaking, all of the instruments used to perform 
EHS activities will need to be able to operate at lower ambient pressures corresponding to an 8/32 
environment. In particular, the current compound-specific analyzers for combustion products (CSA-CP) 
and compound specific analyzers for oxygen (CSA-O2) are currently rated to operate no lower than 13.9 
psi and 9.5 psi, respectively [188]. These and other air sampling devices will especially need to be 
modified and/or tested to work in an 8/32 environment. 
The Health Maintenance System (HMS) will enable nominal and contingency evaluation of crew health 
and provide treatment for a variety of illnesses and injuries. All medical hardware will also need to be 
certified to operate in an 8/32 environment. Additionally, air-dependent diagnostic hardware may have 
to be modified (e.g., blood pressure cuffs) or substituted with devices that are not air dependent (e.g., 
air-puff tonometer). In terms of therapeutics, medications may or may not be more stable in a reduced 
O2 environment, given its combination with higher space radiation. Capability for supplemental O2 and 
mechanical ventilation will be needed to treat a subset of conditions on the Exploration Medical 
Conditions List – both will have to be compatible with the spacecraft atmosphere. A defibrillator to treat 
sudden cardiac arrest or arrhythmia will also have to pose minimal fire risk.  
Human Health and Performance Disposition of the 8/32 Environment 
Based on the literature described in the paper, it is clear that the addition of HH to the spaceflight 
environment presents substantial concerns for human health and performance. A central theme from 
this review is our collective ignorance of the integrated physiologic response to living and working in a 
hypobaric, mildly hypoxic, hypogravity and possibly hypercapnic environment. The goal for any manned 
vehicle should be to operate under normoxic conditions, if possible. If mild HH is required to facilitate a 
rapid EVA capability, then the right balance needs to be achieved for when to utilize this environment 
and then for what duration.  
With an upfront understanding of the need to maintain low ppCO2 values, future spaceflight vehicles 
can be designed to operate the internal environment much lower than what is currently experienced on 
the ISS. Because elevated CO2 is likely to exacerbate acclimatization to and the symptoms associated 
with hypoxia, we recommend that the CO2 Spacecraft Maximum Allowable Concentration (SMAC) be 
updated to reflect the need for lower ppCO2. Work to update the CO2 SMAC is currently supported by 
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the Space Medicine and Toxicology groups and is expected to be included with the next open call for 
updates to the Human Integration Design Handbook. 
Unlike ppCO2, nothing can be done to alter the gravity environment of future exploration destinations. 
Gravity is the perfect antidote for many of the negative adaptations to the spaceflight environment. It is 
unclear to what degree lunar or Mars gravity may mitigate some of these negative changes. As we have 
stated previously, our concern is adding HH to the hypogravity (especially microgravity) and elevated 
ppCO2 spaceflight environment. Of possible destinations, the moon and Mars both provide gravity and 
are the DRMs considering employment of the 8/32 environment for longer periods of time. 
Although decreasing ppCO2 and operating in a gravity field both provide positive benefits, only an 
increase in ppO2 will truly reduce the hypoxic dose. Before any forward work evaluating the 8/32 
environment, we recommend that the trade space should be reevaluated for any achievable increase in 
ppO2. Any increase in ppO2 would help alleviate the hypoxia mediated symptoms. Enrichment to 38% O2 
would meet the current NASA-STD-3001 requirements for a cabin ppO2 > 155 mmHg, but enrichment to 
40% O2 at 8 psia would be considered truly normoxic based on PIO2. 
Available ppO2 Enrichment from 8/32 to 8.2/34 
At nearly the same time that work on this report began, the NASA EAWG effort was revisited with a new 
working group title: Exploration Atmosphere Action Team. Within the context of recent Exploration 
Atmosphere Action Team meetings, the HRP 8/32 Tiger Team has been acting as the Human Health and 
Performance (HHP) subteam, which is one of five subteams including Flammability/Materials, ECLSS, 
Operations/EVA and Vehicle Design. The HHP subteam met separately with the other subteams to 
evaluate whether there was any available trade space to enrich the ppO2.  
The 8 psia cabin atmosphere was set by two primary factors: 1) DCS mitigation and 2) suitport 
operations. For DCS mitigation, any increase in cabin pressure would increase prebreathe time and 
therefore would not be acceptable unless the FIO2 could be enriched to maintain the ppN2 at equivalent 
or lower levels than the 8/32 environment. For suitport operations, we learned that the suitport was not 
rigidly locked in to 8 psia, but rather was compatible up to 8.3 psia. Changing the environment from 
8/32 to 8.3/32 does enrich the ppO2 slightly, but the offsetting increase in prebreathe does not make 
this an acceptable choice alone. 
The 32% O2 limit was chosen for flammability concerns. Upon review of the EAWG final report, it was 
stated that a 36% O2 cabin atmosphere would be possible with current materials [1]. Discussions with 
the ECLSS subteam did indicate a need for some control box limits, so we settled on 34% as a target with 
an acceptable upper limit of 36%. The final consensus of the HHP subteam was to increase the PB to 8.2 
psia and the O2% to 34% and suggest a control box of 8.1 to 8.3 psia and 33.5% to 35% O2. This 
improvement was deemed acceptable by the other subteams and has become a consensus 
recommendation for forward work and development from the Exploration Atmospheres Action Team. 
Although the change from a target setpoint of 8/32 to 8.2/34 seems minor, it provides a substantial 
reduction in hypoxic dose without a change to ppN2, which provides physiologic relief without negating 
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any of the operational benefits of suitport and reduced prebreathe. Table 5 provides the comparison of 
key physiologic parameters showing an overall increase of 11 mmHg to PAO2, a reduction of over 610 m 
(2,000 ft) of equivalent air altitude, and no change to ppN2. 
 
8.2/34 Comparison to 10.2/26.5 
One serendipitous finding was that 8.2/34 is almost physiologically equivalent to the atmosphere of 10.2 
psia and 26.5% O2 used on the shuttle. A comparison of the two environments is shown in Table 6 
demonstrating that the two environments are almost equivalent from a hypoxic dose, but that 8.2/34 
presents a much lower tissue N2 saturation level.  
 
Any human health and performance data available from missions employing the 10.2/26.5 environment 
may be helpful toward understanding the implications of employing a mildly hypoxic environment 
during flight. Table 7 describes the number of days at 10.2/26.5 as well as the crew size and total man 
days. Days at 10.2/26.5 were calculated based on the assumption that cabin pressure was reduced on 
flight day 2 and held there until the completion of the last EVA.  
The average duration at 10.2/26.5 was 6 days, with 22 of the 34 missions depressing to 10.2/26.5 for 
somewhere between 5 to 7 days. The longest mission using 10.2/26.5 was for 14 days, but that was only 
one mission and the next-longest missions were 9 days.  
  
Table 5. Comparison 8/32 and 8.2/34 Environments with Reference to Earth Normal Atmosphere 
PB 
psia 
O2% 
ppO2  
mmHg 
PAO2 
mmHg 
EAA 
m (ft) 
ppN2  
mmHg 
14.7 21 160 109 0 600 
Earth normal atmosphere given above for reference 
8.0 32 132 77  1880 (6170) 281 
8.2 34 144 88  1213 (3980) 280 
Difference +12 +11 -667 (-2190) -1 
 
Table 6. Comparison of the 8.2/34 Environment to the Shuttle 10.2/26.5 Atmosphere 
PB 
psia 
O2% 
ppO2  
mmHg 
PAO2 
mmHg 
EAA 
m (ft) 
ppN2 
(mmHg) 
10.2 26.5 140 87 1265 (4150) 388 
8.2 34 144 88 1213 (3980) 280 
Difference +4 +1 -170 -108 
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Table 7. Spaceflight Experience in at the 10.2 psia / 26.5% O2 Environment 
Flight Launch Landing 
Crew 
Size 
Last EVA 
Days at 
10.2/26.5 
Man Days at 
10.2/26.5 
STS-41B 02/03/1984 02/11/1984 5 02/09/1984 6 30 
STS-41C 04/06/1984 04/13/1984 5 04/11/1984 5 25 
STS-41G 10/05/1984 10/13/1984 7 10/11/1984 6 42 
STS-51A 11/08/1984 11/16/1984 5 11/14/1984 6 30 
STS-51D 04/12/1985 04/19/1985 7 04/16/1985 4 28 
STS-51I 08/27/1985 09/03/1985 5 09/01/1985 5 25 
STS-61B 11/26/1985 12/03/1985 7 12/01/1985 5 35 
STS-37 04/05/1991 04/11/1991 5 04/08/1991 3 15 
STS-49 05/07/1991 05/16/1992 7 05/14/1992 7 49 
STS-54 01/13/1993 01/19/1993 5 01/17/1993 4 20 
STS-51 09/12/1993 09/22/1993 5 09/16/1993 4 20 
STS-61 12/02/1993 12/13/1993 7 12/08/1993 6 42 
STS-64 09/09/1994 09/20/1994 6 09/16/1994 7 42 
STS-69 09/07/1995 09/18/1995 5 09/16/1995 9 45 
STS-72 01/11/1996 01/20/1996 6 01/17/1996 6 36 
STS-76 03/22/1996 03/31/1996 6 03/27/1996 5 30 
STS-82 02/11/1997 02/21/1997 7 02/17/1997 6 42 
STS-86 09/25/1997 10/06/1997 7 10/01/1997 6 42 
STS-87 11/19/1997 12/05/1997 6 12/03/1997 14 84 
STS-88 12/04/1998 12/15/1998 6 12/12/1998 8 48 
STS-96 05/27/1999 06/06/1999 7 05/29/1999 2 14 
STS-103 12/19/1999 12/27/1999 7 12/24/1999 5 35 
STS-101 05/19/2000 05/29/2000 7 05/21/2000 2 14 
STS-106 09/08/2000 09/20/2000 7 09/17/2000 9 63 
STS-92 10/11/2000 10/24/2000 7 10/18/2000 7 49 
STS-97 11/30/2000 12/11/2000 5 12/07/2000 7 35 
STS-98 02/07/2001 02/20/2001 5 02/14/2001 7 35 
STS-102 03/08/2001 03/21/2001 7 03/12/2001 4 28 
STS-100 04/19/2001 05/01/2001 7 04/24/2001 5 35 
STS-104 07/12/2001 07/24/2001 5 07/17/2001 5 25 
STS-105 08/10/2001 08/22/2001 7 08/18/2001 8 56 
STS-108 12/05/2001 12/17/2001 7 12/10/2001 5 35 
STS-109 03/01/2002 03/12/2002 7 03/08/2002 7 49 
STS-125 05/11/2009 05/24/2009 7 05/18/2009 7 49 
Total 202 1,252 
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Human Health and Performance Risk Profile Changes from the 8/32 to 8.2/34 
Environment 
The analysis of potential human health and performance risks associated with the 8/32 environment 
indicated that many concerns warranted forward work, and that some concerns – such as an 
exacerbation of the VIIP syndrome – might preclude the use of the 8/32 environment. The change from 
8/32 to 8.2/34 does not affect any of the EVA or pressure mediated concerns; however, for the hypoxia-
related concerns, this change should provide significant improvement to the overall human health and 
performance risk profile. Although a quantified evidence-based likelihood and consequence analysis is 
not provided for each of the hypoxia mediated concerns, it is likely that a comparison of 8/32 to 8.2/34 
would show a reduction in the likelihood and/or consequence for every hypoxia mediated symptom. 
This ppO2 improvement may be enough to even eliminate some of the potential concerns. 
One additional implication is that the independent pressure effect on hypoxic symptoms seems to be a 
function of hypoxic dose. The greater the hypoxic dose, the less an NH simulation is valid. The 8.2/34 
environment with an EAA of approximately 1,219 m (4,000 ft) might be at a threshold for which 
simulating this environment could adequately be performed using a reduction in the FIO2 rather than 
having to use an O2-enriched capable hypobaric chamber. 
Based on the acceptance of 8.2/34 within the NASA engineering  and materials community and the 
expected human health and performance risk reduction, it is recommended that forward work including 
human research should be performed at the revised 8.2/34 environment rather than 8/32.  
Although the shift from 8/32 to 8.2/34 reduces the general concerns for impaired human health and 
performance, it does not eliminate all these concerns. Therefore, the overall amount of initial 
recommended forward work is likely to be the same in either environment. The difference is that there 
is a greater expectation that these studies may demonstrate the acceptability of the 8.2/34 environment 
and thus require less follow-up work and environmental countermeasure development. 
Recommendations and Forward Work  
This section will describe the suggested research needs and forward work to prepare for this 
environment. In some cases, this work is already being done and we have highlighted what specific HRP 
risks need to be better understood. The remaining recommendations will focus on suggested new areas 
of human research and will describe technical recommendations for implementing the 8.2/34 
environment, including considerations for how to transition to this environment. 
Additional Analyses Needed for 8.2/34 Environment 
The primary purpose of this paper was to evaluate the human health and performance risks associated 
with the 8/32 environment. With a shift now to the 8.2/34 environment, we suggest two additional 
analyses as follow-on efforts to this paper. 
1. Literature review of very mild altitudes up to 1,830 m (6,000 ft). 
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2. Mining of human health and performance data from the 10.2/26.5 shuttle exposures. This effort 
would provide a look into the short-term effects of mild hypoxia in the spaceflight environment. 
Current Research Efforts in Need of Better Understanding 
Certain risks are not currently well understood. In some cases, it was the uncertainty associated with 
these risks more than the addition of HH that was of concern. These current HRP risks include VIIP, 
immune dysfunction and OSaD, which are not well understood, and many of the challenges of the 
Exploration-class missions including longer durations and mild hypoxia and the cycling between the 
hypoxic IVA and slightly hyperoxic EVA environment. Continued research into the elevated ppCO2 levels 
on the ISS and how this increased level affects human health and performance is needed. Additional 
research not directly associated with, but highly related to, the 8.2/34 environment would be the work 
needed to mitigate the risk of crewmember injury during EVA, work done to optimize performance in 
the EVA suit, and human factors engineering efforts to optimize vehicles for habitability. 
Proposed New Research Needs  
This section provides initial recommendations for research studies to aid our understanding of human 
adaptation to the 8.2/34 environment in conjunction with the spaceflight environment. These research 
needs are described at a very high level. 
1. Validation of the 8.2/34 DCS mitigation strategy through hypobaric chamber studies – if DCS is 
not successfully mitigated with the 8.2/34 environment, then there is a need to reevaluate the 
atmosphere, operational concepts, prebreathe requirements, EVA frequency, and many other 
factors that are related to every other follow-on research study. Therefore, we recommend that 
the validation of the 8.2/34 environment for DCS mitigation is recommended to be the first 
major study associated with the 8/32 environment. 
2. Short-term (7- to 14-day) exposures to the 8.2/34 environment using a hypobaric chamber that 
include a mission-like timeline, EVA simulations and the expected level of ppCO2 also included. 
These 1- to 2-week exposures would allow several risks to be evaluated simultaneously, 
including VIIP, AMS, sensorimotor, sleep, OSaD, exercise, cardiovascular, immune, nutrition, 
bone, behavioral health, and possibly other concerns. Much of this work could be combined into 
work described in recommendation #1. Where possible, it would be beneficial to include an 
additional exposure using NH to evaluate the possibility of an independent pressure effect 
worsening the hypoxic dose at 8.2/34. 
3. Longer-term exposures (>14 days) to the 8.2/34 environment. Results of recommendations #2 
will help to determine what risks need further evaluation. Although hypobaric chamber usage is 
preferable, many of these evaluations could be performed with NH simulations.  
4. Short- and long-term 8.2/34 exposures including bed rest. Although hypobaric chamber usage is 
preferable, these evaluations could possibly be performed with NH simulations.  
5. Cell culture oxidative stress studies using bioreactor and the appropriate swings between the 
IVA and EVA environments.  
6. Food preparation testing at 8.2 psia is needed to ensure palatability and ensure acceptable 
microbial loads are met. 
41 
 
7. Antarctica offers a mission-like analog to spaceflight that also includes a hypobaric environment 
(2,834 m [9,300 ft]) that may provide an opportunity to evaluate some concerns discussed in 
this paper. 
Flight Demonstration of the 8.2/34 Environment 
Upon completion of the validation of the DCS mitigation strategy and with an initial understanding of 
the short-term hypoxic symptoms, we recommend that the 8.2/34 environment and EVA operations be 
demonstrated in flight at a location with a margin of safety. This could include the ISS or a lunar 
waypoint habitat. 
An alternative to using the 8.2/34 environment would be to employ the physiologically similar 
environment of 10.2/26.5 using the ISS airlock or some other modifiable habitable element. The 
10.2/26.5 environment is already certified for use in the ISS airlock and would allow us to study the 
effects of an alternative atmosphere mixed with the spaceflight environment. If creating a habitable 
element on the ISS is not feasible, an NH simulation using a flight-compatible portable reduced O2 
breathing device could be considered. The crewmember would wear an oronasal facemask connected to 
the reduced O2 source. This may preclude continuous and longer-duration exposures, but could provide 
valuable feedback on how short-duration exposure to hypoxia in the spaceflight environment affects 
cognitive performance and neurophysiology. 
General Technology Recommendations 
This section will recap some of the technical recommendations suggested to certify hardware and to 
mitigate some of the negative physiologic effects of the 8.2/34 and spaceflight environment. 
 Improved CO2 scrubbing will be needed for human habitation of a mildly hypoxic environment 
and is perceived to be quite possible by the NASA engineering community. 
 Guidelines for the ECLSS control box for the 8.2/34 environment need to be further defined. The 
expectation is that the control box can operate in a tighter band around the setpoint than the ± 
0.2 psi and ± 2% O2 described in the EAWG report. 
 Guidance on the rate of change from one atmospheric composition to another will need to be 
generated for the ECLSS controls. 
 Existing CHeCS hardware, new medical hardware, exercise countermeasures, and human 
research equipment will need to be updated to ensure proper operation in the reduced 
pressure of the 8.2 psia environment. 
 Finally, the IMM will need to updated to reflect changes in disease incidence and treatment 
based on the 8.2/34 environment. 
Considerations for Transitioning Between Environments 
This section will summarize some suggested mitigation strategies that will help alleviate symptoms or 
prepare the astronaut to occupy the 8.2/34 spaceflight environment. Gradual decompression from 14.7 
psia to 8.2 psia will diminish many of the acute symptoms such as AMS and hypoxic-related sleep 
problems. Supplemental O2 should be available during vehicle decompressions and throughout the 
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length of the mission should certain crewmembers not adapt as readily as others. This supplemental O2 
will also be used as DCS prevention during this depressurization. 
An exact understanding of atmospheric and tissue inert gas exchange does not yet exist to precisely 
define when the inert gas tension in tissues comes into a new equilibrium after the breathing 
environment has changed. When a significant pressure reduction is used to reduce the tissue N2 tension, 
then there is the additional complication of creating “silent bubbles” in the body that then hinder 
normal tissue N2 exchange with the atmosphere. In the case of the 8.2/34 environment, the pressure 
reduction from 14.7 psia to 8.2 psia is done in concert with an increase in FIO2 from 21% to 34%. Both of 
these changes reduce ambient ppN2 from 600 to 280 mmHg, but there is some uncertainty on when 
tissue N2 tension comes into a new equilibrium. If we accept that a 360-minute theoretical half-time 
tissue compartment is key to our DCS applications, then the mathematics of simple exponential decay 
says that you need four half times (24 hr) to account for 94% of the difference between the initial and 
final tissue N2 tension. Six half times (36 hr) brings the difference to 98% and by 8 half times (48 hr), the 
difference is negligible.  
Based on research experience from the shuttle 10.2 psia staged denitrogenation protocol, it was clear 
that a direct depress to 10.2 psia created “silent bubbles” that manifested 12 to 16 hours later as early-
onset venous gas emboli (VGE) and early onset Type II DCS symptoms while at the EVA pressure of 4.3 
psia. A 60-minute prebreathe was instituted such that the first decompression to 10.2 psia would not 
theoretically supersaturate the 360-minute half-time compartment; the computed tissue ratio was 1.0. 
This removed the early-onset VGE and DCS in subsequent tests of the staged protocol [189]. In keeping 
with this same philosophy, preliminary analysis indicates the need to implement a 180-minute 
prebreathe before depressurization from 14.7 to 8.2 psia to keep the computed tissue ratio at 1.0. Since 
100% O2 is used for the 18-minute prebreathe, the tissue N2 tension is lower than it would be if the 
astronaut was just exposed for 180 minutes to the 8.2/34 environment. So the computed time to 
achieve equilibrium to the 8.2/34 environment is reduced to 45 hours. If an EVA was to be performed 
before saturation at 8.2/34, then additional prebreathe beyond the expected 15 minutes would be 
needed, possibly as much as 30 minutes for the first EVA.  
Crewmembers will need to be trained to understand the symptoms of hypoxia. When the application of 
the 8.2/34 environment is to be employed early in the mission phase, the crewmembers will have to 
adapt acutely to the spaceflight and hypoxic environment at the same time. Critical tasks should be 
avoided and workload stress should remain low during the atmospheric transition period.  
Although hypoxic pre-conditiong is not a mitigation for DCS, it is a technique that uses bouts of hypoxic 
exposure before ischemic insults. This may not directly apply to the astronaut in the spaceflight 
environment, but the effect of pre-exposure to the hypoxic stimulus and how it prepares people to 
tolerate the hypoxic environment on subsequent trials has also been discussed. The degree of hypoxia, 
duration of exposure, and timing of the exposure would need further literature review before 
implementation in the crew training and mission preparation phases.  
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Conclusion 
EVA is at the core of a manned space exploration program. With the 8/32 environment, NASA gains the 
capability for efficient EVA with low risk of DCS, but accrues the additional human health and 
performance risks associated with the addition of HH to spaceflight environment. This literature review 
of the human health and performance risks associated with the 8/32 cabin environment indicated many 
potential areas of concern including increased intracranial pressure, visual impairment, sensorimotor 
dysfunction, and oxidative damage. Forward work would also include validating the DCS mitigation 
strategy, identifying/treating AMS, developing new exercise protocols, effectively preparing food at 8 
psia, ensuring quality sleep, and preventing suit-induced injuries.  
The available engineering trade space provides the opportunity to move from 8/32 to 8.2/34, which 
increases the PAO2 by 11 mmHg and decreases the EAA by more than 610 m (2,000 ft). This significant 
improvement may reduce the likelihood and/or consequence of each discussed hypoxic symptom. 
Although the 8.2/34 environment is an improvement from the 8/32 environment, it does not eliminate 
all human health and performance concerns and needs to be evaluated through appropriately simulated 
research studies before flight implementation. 
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